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STATISTICAL MODELS AND ANALYSIS OF GROWTH PROCESSES IN BIOLOGICAL
TISSUE

by

JUN XIA

Under the Direction of Remus Osan, PhD

ABSTRACT
The mechanisms that control growth processes in biology tissues have attracted continuous
research interest despite their complexity. With the emergence of big data experimental approaches
there is an urgent need to develop statistical and computational models to fit the experimental data
and that can be used to make predictions to guide future research. In this work we apply statistical
methods on growth process of different biological tissues, focusing on development of neuron
dendrites and tumor cells.
We first examine the neuron cell growth process, which has implications in neural tissue
regenerations, by using a computational model with uniform branching probability and a
maximum overall length constraint.

One crucial outcome is that we can relate the parameter fits

from our model to real data from our experimental collaborators, in order to examine the usefulness
of our model under different biological conditions. Our methods can now directly compare
branching probabilities of different experimental conditions and provide confidence intervals for
these population-level measures. In addition, we have obtained analytical results that show that

the underlying probability distribution for this process follows a geometrical progression increase
at nearby distances and an approximately geometrical series decrease for far away regions, which
can be used to estimate the spatial location of the maximum of the probability distribution. This
result is important, since we would expect maximum number of dendrites in this region; this
estimate is related to the probability of success for finding a neural target at that distance during a
blind search.
We then examined tumor growth processes which have similar evolutional evolution in the
sense that they have an initial rapid growth that eventually becomes limited by the resource
constraint. For the tumor cells evolution, we found an exponential growth model best describes
the experimental data, based on the accuracy and robustness of models. Furthermore, we
incorporated this growth rate model into logistic regression models that predict the growth rate of
each patient with biomarkers; this formulation can be very useful for clinical trials. Overall, this
study aimed to assess the molecular and clinic pathological determinants of breast cancer (BC)
growth rate in vivo.

INDEX WORDS: Neuronal Tree, Stochastic Models, Maximum Length Constraint, Breast
Cancer, Tumor Size Growth Rate, Survival Analysis, Kaplan-Meier Estimate, Cox Proportional
Hazard Ratio, Model Selection
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1
1.1

INTRODUCTION

Motivation for Studying Neural Growth

Injuries to the central nervous system often result in extreme functional deficits because of
physical damage to neurons in the brain and/or spinal cord. Currently, there is no
neuroengineering solution to either traumatic brain injury (TBI) or spinal cord injury (SCI) despite
intense research in both of these areas, likely because the central nervous system has a limited
capacity to regenerate itself [1]. Especially in the mammalian central nervous system, the
regeneration ability of axons is quite limited after injury. Thus, the axonal damage will lead to
functional deficits, such as paralysis, Alzheimer and so on. Therefore, in the recovery process
after central nervous system injury, axonal regeneration plays a key role and influences the speed
of recovery. In this study, we model neuronal growth with the aim that the insight gained would
help develop therapies aimed at fostering connection regrowth.
With the subject of regeneration in mind, we assumed that the neural tree is formed as a result
of a branching process, which is subjected to limited resources, such as maximum total neural
tree length [2]. Since traditional branching processes do not have such limitations, making it easy
to obtain the mean and variance along with each step, we aim to extend that formula to the
practical process with the limitations mentioned above. We believe that the regeneration
process with limited resources can be applied to so many other fields, which have the similar
scenarios; such examples can be seen in the marketplace, nuclear, chemistry and so on. Usually,
for these regeneration processes, we are interested in the size of the whole tree for each step,
under limited resources.
1.1.1

Previous studies

Much effort has been devoted to understanding the mechanisms that govern dendritic
outgrowth in neurons because proper dendrite morphology is essential to neuronal
communication. The shape of the dendritic arbor determines which neurons receive and process
information, thereby affecting postsynaptic activity and the way neurons are integrated into the
network [2]. During disease or after trauma [3], dendritic morphology is often negatively affected,
resulting in either too few or too many dendrites. The structure of the network is then disrupted,
1

which can result in network dysfunction and cognitive deficits. Moreover, it has been shown that
dendrites are not merely passive structures that deliver information to the soma. Rather,
dendrites have the ability to perform computations, influence synaptic output, and regulate
protein translation [4-6]. These studies illustrate the importance of a properly formed dendritic
arbor, which not only receives and conducts information but also influences the nature of the
information.
During neuronal development, dendrite outgrowth is influenced by the simultaneous ingrowth
of axons as well as the formation of synapses. Similar to axonal growth, dendritic growth is
characterized by the appearance of filopodia that may develop into growth cones and lead to
mature branches [5]. Importantly, dendrites are highly dynamic and undergo both growth and
retraction during development, and most filopodia do not develop into dendrites. Early in
development, dendrite outgrowth is encouraged by the presence of synaptic activity, and then
later in development, synaptic activity stabilizes dendrites [5, 7]. While fewer cues are present
during two-dimensional in vitro development, neurons proceed through similar steps, in which
filopodia-like structures develop into immature neurites. One of these neurites becomes the
axon, and the rest may become dendrites if they continue to grow [8,9]. Similar to in vivo
development, neurons that develop in vitro are also highly dynamic. This similarity of maturation
processes allows us to study the effects of extrinsic and intrinsic regulators of branching, and
researchers have identified many of these factors that modulate dendrite number in-vitro and in
vivo [10]. Being able to study neuronal developments in vitro has allowed us and others to
identify the protein-protein interactions and cellular processes necessary for neuronal
development. For example, the Firestein laboratory has identified cytosolic PSD-95 interactor
(cypin) as an intrinsic regulator of dendrite branching [6]. They have found that cypin significantly
increases primary and secondary branching by promoting microtubule polymerization (figure 1).
Additionally, they recently found that brain-derived neurotrophic factor (BDNF), a very wellknown extrinsic growth factor, increases proximal dendrite branching through transcriptional
regulation of cypin [6]. Many other factors have also been shown to modulate dendrite branching
in specific ways; studying neuronal development in vitro is allowing scientists to determine which
factors may be useful as therapeutic strategies for neurodegenerative diseases and CNS injury.
2

Figure 1 Overexpression of vypin from DIV 6-10 increases proximal branching and total dendrite
number but decreases average dendrite length
(A) Representative images of hippocampal neurons overexpressing GFP or GFP-cypin (cypin) from
DIV 6–10. Scale bar = 100 μm. (B) Sholl analysis of all orders of branches (Total Sholl) shows that
overexpression of cypin significantly increases dendrite branching at 0–42 μm from the cell body
(***p < 0.001). Statistics were calculated using Two-Way ANOVA followed by Bonferroni multiple
comparisons test.(C) Overexpression of cypin results in a significant increase in the total number
of dendrites (****p < 0.0001). A total number of dendrites represents the sum of all dendrites,
regardless to what category they belong. Statistics were calculated by unpaired, two-tailed
Student's t-test. (D) Overexpression of cypin results in a significant decrease in the average
length of dendrites (**p < 0.001). The average length is the mean length of all dendrites,
regardless to what category they belong. Statistics were calculated by unpaired, two-tailed
Student's t-test with Welch's correction. Error bars indicate SEM. n = 50 neurons for GFP, and n =
55 neurons for cypin. Figure 1 was reproduced from [1] with the permission from the authors.

To assess the overall shape of the dendritic arbor, several tools have been developed, the most
widely known being Sholl analysis (figure 2) [11]. This method counts dendrites by drawing
concentric circles at fixed distances from the cell body and counting the number of intersections
3

at each distance. When performed manually, the process is time-consuming and prone to errors.
To this end, several groups have developed automated or semi-automated Sholl analysis
software packages to increase the accuracy of results and decrease analysis time. Sholl is an
invaluable tool in the field of neuroscience because it allows for the comparison of branch
number at specific distances from the soma, which provides more information than total branch
number alone. However, statistical analyses such as two-way analysis of variance only take into
account only differences at specific distances, not between the different probability distributions.
For example, a Sholl curve shifted to the left or the right from the control curve will show
statistical significance at several locations, but no single parameter indicates this specific shift.
With our model, we were also able to discriminate between different Sholl curves of control
neurons versus treated neurons.

Figure 2 Three different scenarios during the neural tree regeneration [14].
Figure 2 Time sequences showing branching and pruning of dissociated E11 chick dorsal root
ganglion neurites. (a) Branching (red arrow) and extension (blue arrowheads) of primary axons.
(b) Extension and retraction (blue arrowheads) of neurite tip. (c) Tertiary branching and pruning
(encircled). Cultures are grown in the presence of glia in 5% CO2/ 37uC on Poly-L-lysine/laminin
in N3 complete serum-free media. Phase- contrasts l i v e imaging at 28 hrs post-plating. The time
interval between acquisitions for each time series is as follows: (a) 30 mins, (b) 75 mins, (c) 75
4

mins. Snapshots are contrast enhanced for visual clarity of the neurites. Figure 2 was reproduced
with permissions from authors.

While the arborization patterns of neurons have received extensive attention in experiments, it
is not clear what the rules are that govern the final shape of neurons despite multiple
computational models that were proposed [2, 4, 6,12]. Some of the simplest models assume that
outgrowth is a result of a stochastic process, where the neuron starts with an initial branch that
generates additional branches uniformly at the periphery. Osan et al. ([2]) examined these
growth rules in a computational model [2] in which a blind search for targets was performed. To
accomplish this, they cultured neurons under conditions mimicking SCI, then compared the
results with our model. In order to derive analytical expectations for these computations, they
also introduced the use of a probabilistic realization of all possible trees to compute the average
length of no-longer-evolving branches. In this current study, we extend these results to
determine the probabilistic performance profiles for all trees of a given maximum length.
Importantly, we then show that our model is consistent with experimental data gathered from
hippocampal neurons cultured in vitro.
1.1.2 Modeling neural dendritic tree growth using stochastic processes
Branching process is a Markov process that models the regeneration of population under the
assumption that each individual in the generation k can produce a random number of individuals
for next generation k+1. In our case, each branch of the neural tree can generate a random
number of next level of branches.
In our study, we first made some naïve assumptions, for example, the probability for each
individual to produce next generation is independent of others. The probability mass function for
offspring is often called the offspring distribution and is given by
𝑝𝑖 = 𝑃(𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑜𝑓𝑓𝑠𝑝𝑟𝑖𝑛𝑔 = 𝑖),
𝑓𝑜𝑟 𝑖 = 0, 1, 2, . ..
We first assume that each individual in our model can only generate no more than 2 individuals
5

for next generation, which means that:
𝑝𝑖 = 0

𝑓𝑜𝑟 𝑖 > 2

This model was introduced by F. Galton, in the late 1800s, to study the disappearance of family
names; in this case 𝑝𝑖 is the probability that a man has 𝑖 sons. We will start with a single individual
in generation 0, and generate the resulting random family tree. This tree is either finite (when
some generation produces no offspring at all) or infinite — in the former case, we say that the
branching process dies out, and in the latter that it survives.
Proposition 1: Any recurrent class is a closed subset of states. [13]
This process is equivalent to a Markov chain, where 𝑋𝑛 is the number of individuals at generation
n. Let’s start with the following observations.
•

If 𝑋𝑛 reaches 0, it stays there, therefore 0 is an absorbing state.

•

If 𝑝0 > 0, 𝑃(𝑋𝑛+1 = 0|𝑋𝑛 = 𝑘) > 0 for all k, which means

•

Therefore, by Proposition 1, all states other than 0 are transient if 𝑝0 > 0; the population
must either die out or increase to infinity. If 𝑝0 = 0, then the population cannot decrease,
and increases each generation with probability at least 1 − 𝑝1, therefore must increase to
infinity.

It is possible to write down the transition probabilities for this chain, but they have an explicit
form, as
𝑃(𝑋𝑛+1 = 𝑖|𝑋𝑛 = 𝑘) = 𝑃(𝑊1 + 𝑊2 + . . . + 𝑊𝑘 = 𝑖)
where 𝑊1 , . . . , 𝑊𝑘 are independent random variables, each with the offspring distribution. Recall
that we are assuming that 𝑋0 = 1.
Let
𝛿𝑛 = 𝑃(𝑋𝑛 = 0)
be the probability that the population is extinct by generation (which we also think of as time) n.
The probability π0 that the branching process dies out is then the limit of these probabilities:

6

𝜋0 = 𝑃(𝑡ℎ𝑒 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 𝑑𝑖𝑒𝑠 𝑜𝑢𝑡) = 𝑃(𝑋𝑛 = 0 𝑓𝑜𝑟 𝑠𝑜𝑚𝑒 𝑛) = lim 𝑃(𝑋𝑛 = 0) = lim 𝛿𝑛
𝑛→∞

𝑛→∞

Note that 𝜋0 = 0 if 𝑝0 = 0. Our main task will be to compute 𝜋0 for general probabilities 𝑝𝑘 .
We start, however, with computing expectation and variance of the population at generation n.
Let µ and 𝜎 2 be the expectation and variance of the offspring distribution, that is,
∞

µ = 𝐸𝑋𝑛 = ∑ 𝑘𝑝𝑘
𝑘=0

and
𝜎 2 = 𝑉𝑎𝑟(𝑋𝑛 ).
Theorem 1: Expectation and variance of sums with a random number of terms: Assume that
𝑋1 , 𝑋2 , … is an 𝑖. 𝑖. 𝑑 sequence of random variables with finite 𝐸(𝑋) = 𝜇 and 𝑉𝑎𝑟(𝑋) = 𝜎 2 . Let
𝑁 be a nonnegative integer random variable, independent of all 𝑋𝑖 , and let 𝑆 = ∑𝑁
𝑖=1 𝑋𝑖
Then
𝐸(𝑆) = 𝜇𝐸(𝑁)
𝑉𝑎𝑟(𝑆) = 𝜎 2 𝐸(𝑁) + 𝜇 2 𝑉𝑎𝑟(𝑁)
Let 𝑚𝑛 = 𝐸(𝑋𝑛 ) and 𝑣𝑛 = 𝑉𝑎𝑟(𝑋𝑛 ) . Now, 𝑋𝑛+1 is the sum of a random number, which
equals𝑋𝑛 , of independent random variables, each with the offspring distribution. Thus, we have,
by Theorem 1 above,
𝑚𝑛+1 = 𝑚𝑛 µ,
and
𝑣𝑛+1 = 𝑚𝑛 𝜎 2 + 𝑣𝑛 µ2 .
Together with initial conditions 𝑚0 = 1, 𝑣0 = 0, the two recursive equations determine 𝑚𝑛
and 𝑣𝑛 . We can very quickly solve the first recursion to get 𝑚𝑛 = µ𝑛 , and consequently we
obtain:
𝑣𝑛+1 = µ𝑛 𝜎 2 + 𝑣𝑛 µ2 .
7

This recursion has a general solution of the form 𝑣𝑛 = 𝐴µ𝑛 + 𝐵µ2𝑛 . The constant A must
satisfy
𝐴µ𝑛+1 = 𝜎 2 µ𝑛 + 𝐴µ𝑛+2 ,
so that, when µ ≠ 1,
𝐴 =

𝜎2
.
µ(1 − µ)

From 𝑣0 = 0, we get 𝐴 + 𝐵 = 0 and the solution is given in the next theorem.
So, we have the Theorem1.1.1: Expected 𝑚𝑛 and variance 𝑣𝑛 of the 𝑛𝑡ℎ generation count
We have
𝑚𝑛 = 𝜇 𝑛
𝑎𝑛𝑑
𝜎2
𝜎2
𝜇𝑛 −
𝜇 2𝑛 𝑖𝑓 𝜇 ≠ 1
𝑣𝑛 = { 𝜇(1 − 𝜇)
𝜇(1 − 𝜇)
{
𝑛𝜎 2
𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒

1.1.3 Our study on the discrete neural growth model under limited resource
condition
The structure of neuronal trees is essential for individual cell and network function, yet neuronal
synaptic and membrane dynamics have received significantly more attention in the experimental
and computational neuroscience community.

This is in part due to the fact that our

understanding of experimental data has traditionally focused on descriptive approaches of the
network structure, and conversely, the corresponding mathematical models are much less
developed.
In the current study, we extend our work to hippocampal neurons that develop normally. We
study these neurons as they are often damaged as a result of traumatic brain injury and are also
subject to alteration due to neurodegeneration, such as Alzheimer’s Disease, or neurocognitive
disorders, such as schizophrenia. Our results can be used to determine the probabilistic
8

performance profiles for all trees of a given maximum length. Importantly, we then show that
our model is consistent with experimental data gathered from primary cultures of rat
hippocampal neurons. More precisely, the Sholl curves predicted by our model exhibit the same
trends seen in the experiments: a region of geometric growth in the nearby regions, which soon
slows down to produce a peak in expected number of branches that is followed by a steady
approximately geometric decrease at long distances. Furthermore, our model allows us to
generate accurate fits of the experimental data using a small number of parameters, with the
uniform branching probability playing a crucial role. Based on our results, we now have a baseline
for dendritic growth and can compare this model to ones in which neurons are damaged due to
trauma or disease, in order to work toward predicting which intrinsic or extrinsic factors can be
targeted therapeutically to treat patients. Our goal is to compare features such as the branching
probabilities under different conditions and generate statistical tests for these comparisons in
order to determine statistical significance. Our future work will examine the effects induced by
uniform rate pruning as well as parameter-based branching and pruning.
1.2

Motivation for Tumor Growth Project
1.2.1 Previous study

Breast cancer is the heterogeneous disease with different clinicopathological features,
recurrence patterns, and survival. [14] The major molecular subtypes: estrogen receptor (ER)
positive, human epidermal growth factor receptor (HER2) positive and Triple Negative are widely
used to predict prognosis and response to treatment in breast cancer patients [15]. Risk factors
for breast cancer range from excessive use of exogenous hormones to age at menarche and age
at menopause. [16] Family history of breast cancer is also considered a highly important risk
factor while the non-reproductive factors include age, high BMI, the excessive alcohol intake,
sedentary lifestyle, poor diet and exposure to medical radiation. [16-18]
Breast cancer has highly variable rates of growth. Contemporary thoughts assume that the gross
tumor growth rate decelerates with increasing tumor mass. The study of tumor growth rates is
necessary to understand the biology and natural history of the malignant diseases[19]. In
developed countries, mammography screening is becoming an established part of health services.
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However, there is an ongoing discussion related to optimization of the mammography screening,
including the determination of optimal time intervals between screening and which age group to
initiate. Therefore, the knowledge of tumor growth is important in planning and evaluation of
screening programs. [20] Despite these facts, Mammography has a number of limitations
wherein it yields false-positive results, leading to an increased number of breast biopsies
especially among young patient. [21] Breast cancers that are detected in the interval after a
negative mammographic result are the interval cancer. [22] It is now a known fact that breast
cancer screening has been proven to save lives and helps in better treatment regimens wherein
Mammography remains the mainstay of screening[23]. But In US, the overall progress in reducing
the breast cancer-related mortality following screening has not been reduced instead the
probability of death is snoring. [24]
The tumor growth rate has not been implicated as a prognostic variable in clinical practice
because of its difficulty in evaluating it in the short interval of diagnosis and treatment. However,
Yoo demonstrated that there is no any association of tumor growth rate with patient’s survival.
[25] Also, in the study carried out by Tubiana [26], there was no any survival difference between
the subgroups of patients with rapid or intermediate growth rate after the follow-up exceeding
8 years. [26]
In vivo, breast cancer growth rate is carefully regulated. There is a precise balance between
growth fraction – the proportion of tumor cells that are proliferating – rate of tumor cell loss by
apoptosis, (and necrosis) and cell doubling time. [27, 28] Heterogeneities in growth rate between
individual tumor cells, the degree of angiogenesis, [29] and interactions between the tumor and
surrounding stromal cells also play a part. [30] The growth rate holds vital importance in
prognostication, as it been shown that tumors with a faster growth rate in vivo, are more
aggressive and thus offer a worse prognosis. [31, 32]
Essentially, tumor growth progression is characterized by a net increase in the number of tumor
cells, which could be due to increased proliferation and/or decreased apoptosis or both. Although
a lot of such correlative studies are available in cultured cells, no study has yet systematically
evaluated proliferation and apoptosis during in vivo progression of tumor growth. From a clinical
10

standpoint, several proliferation markers have demonstrated utility in the clinic for
prognostication. The study aims to identify correlations between clinic-pathological parameters,
biomarker expression and in vivo tumor growth rate, determined by the change in tumor size
between sequential mammograms. Tumor growth rate may be a significant consideration when
subtyping breast carcinomas, and consequently could be important in determining patient
outcome. The study is expected to improve our understanding of breast cancer biology and
growth determinates but also will provide prognostic information and evidence-based data that
can be used in the medicolegal practice.
1.2.2 Models for tumor growth process
There are so many continuous models for the growth rate that can be used to model tumor
growth [33-36]. The simple list one is linear growth model:
𝑉(𝑡 = 𝑡1 ) = 𝑉0 + 𝛼(𝑡1 − 𝑡0 )
Here 𝑉0 is the initial tumor size, 𝑡0 and 𝑡1 are the time of diagnostic and time of revisit, 𝛼 is the
tumor growth rate. And we have the result for growth rate is:
𝛼=

𝑉𝑡1 − 𝑉𝑡0
𝑡1 − 𝑡0

We also tried the second model, which is Exponential Linear Model [38]:
𝑑𝑉
= 𝑎0 𝑉,
𝑡≤𝜏
𝑑𝑡
𝑑𝑉
= 𝑎1 ,
𝑡>𝜏
𝑑𝑡
{ 𝑉(𝑡 = 0) = 𝑉0
Here, coefficient 𝑎0 is the coefficient for the exponential growth part, which is the parameter
that we are interested in predicting. The coefficient 𝑎1 is the coefficient for the linear growth
part.
The theory behind this model is that all cells proliferate with constant cell cycle duration𝑇𝑐 . Thus,
this leads to an exponential growth model. This model also valid when the fraction of proliferative
of the tumor size is constant or when the cell cycle period is a random variable with exponential
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distribution. Here for our model, we assume the exponential phase to be followed by a linear
growth phase.
In our study, since there were only have two screening results and only a limited number of
samples (less than 100 trials), we simply set 𝑇𝑐 to be the maximum of time between two
screenings. Then the solution to obtain the growth rate for our model is:

𝑎0 =

𝑉
log (𝑉1 )
0

𝑡1 − 𝑡0

=

log(𝑉1 ) − log(𝑉0 )
𝑡1 − 𝑡0

Where 𝑉0 and 𝑉1 are the tumor volume at the time of diagnosis and time of the first revisit, at
the time 𝑡0 and 𝑡1 respectively.
The last model we tried to fit the growth model is Logistic and Gompertz models [36]:
𝑑𝑉
𝑉
= 𝑎𝑉 (1 − )
{ 𝑑𝑡
𝐾
𝑉(𝑡 = 0) = 1
Here 𝑎 is a coefficient related to proliferation kinetics, 𝐾 stands for the carrying capacity, where
all tumor volumes converge. This model can be interpreted as growth model under limited
carrying capacity. Again, due to lack of enough data and making calculation simple, we set the
carrying capacity to be the maximum of tumor size screened. Here an approximation of the
solution for the growth rate is:
𝑎=

log(𝑉𝑡1 ) − log(𝑉𝑡0 )
(1 − 𝑒 −

𝑡1 −𝑡0
𝐾 )

1.2.3 Application of growth rate models in the survival analysis
As described above, the growth rate has been less studied or used in clinical trials to classify the
type of breast cancer patients. Part of the reason is it is not linked to biomarkers, which are widely
used for prognostication. In order to connect change in tumor size and type of breast cancer, we
further apply survival analysis on the data.
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We first try to find the best cut point for the growth rate, which would be used later to separate
fast growth patients from slow growth patients. The practice of dichotomizing continuous
covariates is widely used in medical and epidemiological research for both clinical and statistical
reasons. From the clinical perspective, we can use a cutpoint split continuous variables into ‘low’
and ‘high’, establishing a threshold for future studies. Using the criteria, patients can be classified
into these two groups and their prognosis can be estimated, which will be used for choosing
proper treatments. From the statistical perspective, binary covariate provides a simpler
interpretation of effect measures, such as odds ratios and relative risks. In our study, by
comparing hazard ratios between groups, we can have not only a clearer understanding of the
results but also an easier way for future implementation. Another benefit of using binary
covariates is that one does not need to check statistical assumptions before using them to build
up our model [39].
The way to choose the best cut point is choosing the one that provides the greatest difference
between survival functions of two groups. After that, we fit a logistic regression to predict growth
rate mode with biomarkers, such as KI67 scores, CASPS3 scores.

1.2.4 Using survival analysis to analyze breast cancer data
Survival analysis is a set of methods for analyzing data with the outcome as ‘time to event’, which,
in our study, is time to death and later was extended to time to recurrence.
There are several common terms defined in our survival analysis:


Event: In our study, the events we are interested in is Death and Recurrence;



Time: The time from the diagnosis to the event of interest;



Censoring: If a subject does not have an event during the observation time, then these
cases are defined as censored. There is no information about the occurrence of the event
after observation;



Survival function: The probability that a patient survives longer than time 𝑡, in which
‘survives’ was defined as still being alive at observation time.
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In our study, we mainly used Kaplan-Meier curves and Cox proportional hazard regression to
analyze the breast cancer data.
Kaplan-Meier curve is a non-parametric statistic used to estimate the survival function, which
was used in our study to measure the length of survival time for patients with breast cancer [40].
There are three assumptions that are important in this analysis. First, all the censored patients
have the same survival pattern as those patients who remains in the study. Secondly, all patients
have the same survival probability no matter when they joined the study. Thirdly, we can only
observe the event at the specified time, which means we can only know what happened when
carrying out the follow-up. And the survival probability at particular time is calculated by the
formula given below [40]:
𝑆𝑡 =

𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑢𝑏𝑗𝑒𝑐𝑡𝑠 𝑟𝑒𝑚𝑎𝑖𝑛𝑒𝑑 𝑎𝑙𝑖𝑣𝑒 𝑎𝑡 𝑒𝑛𝑑 𝑡𝑖𝑚𝑒
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑢𝑏𝑗𝑒𝑐𝑡𝑠 𝑎𝑙𝑖𝑣𝑒 𝑎𝑡 𝑡ℎ𝑒 𝑠𝑡𝑎𝑟𝑡 𝑡𝑖𝑚𝑒

Another survival analytic tool we used is Cox proportional hazard model, where the hazard at
time 𝑡 for an individual with covariates 𝑥𝑖 is assumed to be
𝜆𝑖 (𝑡|𝑥𝑖 ) = 𝜆0 (𝑡)exp(𝑥𝑖 ′𝛽)
In this model, 𝜆0 (𝑡) is a baseline hazard function that describes the risk for individuals with 𝑥𝑖 =
0. In our study, we select the lowest level of each biomarker to be the baseline. Here exp(𝑥𝑖 ′𝛽)is
the relative risk, a proportional increase or decrease in risk, which is what we want to estimate
from the model.

1.2.5 Fit Logistic regression model to predict growth rate with biomarkers
In our study, we tried to build up model to predict the type of growth rate for each patient with
their prognostic characteristics. This model will be used in the future to predict whether the
patient has a fast growth rate or a slow growth rate, which indicates whether he or she would
face a high or low risk to death.
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The model we choose is logistic regression model. There are several reasons why we made this
choice:


The outcome of our data is a categorical variable, so our model should be the probability
of belonging to each class.



Our model would be applied to the clinical practice, which means our model should not
be too complicated for implementation.



When selection the biomarkers in the model, the logistic regression is an easy way to
compare the results from different models. We choose the best model based on the
predicting accuracy and model diagnostic result.

1.2.6 Extension of the survival analysis to recurrence of breast cancer
After we obtain the connection between growth rate and risk to death, we want to extend the
usage on more clinical practice. Since the idea of survival analysis can be applied to some other
time to event study, we just need to change the event of interest to the recurrence of breast
cancer. Since people from public health are interested in comparing risks to recurrence among
difference races, I extended the survival analysis to the recurrence of breast cancer and tried to
compare that of patients with different races.
Clinical studies have revealed a higher risk of breast tumor recurrence in African-American (AA)
patients compared to European-American (EA) patients, contributing to the alarming inequality
in clinical outcomes among the ethnic groups. However, distinctions in recurrence patterns upon
receiving hormone, radiation, and/or chemotherapy between the races remain poorly
characterized.
The significant divide in breast cancer mortality between African-American (AA) and EuropeanAmerican (EA) patients remains a challenge for clinicians. Despite a similar number of reported
incidences of breast cancer among AA and EA women, AAs experience notably higher severity in
clinical outcomes and exhibit a 40% higher death rate than EAs among premenopausal and
menopausal breast cancer patients [41-43]. Recurrent breast cancer has impeded successful
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management of the disease for decades and is one of the primary factors for this racial division
in prognosis [44]. Statistics demonstrate that approximately 40% of all breast cancer survivors
will experience a recurrence episode during their lifetime, which has been suggested to play a
principal role in breast cancer mortality [45]. Clinical studies have revealed a higher risk of
recurrence in AA compared to EA, presumably contributing to the inequality in clinical outcomes
among the ethnic groups [41]. This statistic has provided an impetus for clinicians to devise and
implement robust prognosticative measures to preclude recurrence in AA breast cancer patients.
However, distinctions in recurrence rates and patterns following various forms of treatment
between the races have not been thoroughly evaluated. This warrants more investigation to
potentially attenuate the observed racial disparity in recurrence in the clinic. Hence, we
conducted a large institutional study based in Atlanta, Georgia, in which we analyzed rates and
patterns of tumor recurrence post hormone, radiation, and chemotherapy among AA and EA
breast cancer patients. This retrospective clinical study uncovered previously unrecognized
distinctions in recurrence patterns following each conventional form of treatment among racially
distinct breast populations and may impart valuable clinical insight into preclusive measures for
mitigating the ethnic disparity in breast tumor recurrence.
We compared patterns and rates (per 1000 cancer patients per 1 year) of recurrence following
each form of treatment between AA (n=1850) and EA breast cancer patients (n=7931) from a
cohort of patients (n=10504) treated between 2005-2015 at Northside Hospital in Atlanta, GA.
Multivariate models were used to examine the effect of age, grade, and stage on our results and
95% confidence intervals were used to determine if there are significant difference between the
two groups.
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2
2.1

METHODS

Neuronal Culture and Analysis

We used data from the Firestein laboratory at Rutgers University to verify the validity of our
models against experimental results, all the data were used with the permission from them. The
neuronal images used for this study were previously analyzed [46]. But were reanalyzed using
the Firestein laboratory’s method of semi-automated Sholl analysis, called Bonfire [47, 48]. The
Sholl curves generated for this study were not included in previous study [46]. The experimental
procedures used are as follows Cell culture, transfection, and immunostaining:
Hippocampal neurons were isolated from embryonic rats at 18 days of gestation (E18) as
previously described [47, 48]. Briefly, the hippocampi from Sprague-Dawley rats were isolated
and mechanically dissociated. Hippocampal neurons were then plated on poly-D-lysine (PDL)coated glass coverslips (12 mm diameter) at a density of approximately 1800 cells/mm2. Cells
were cultured in Neurobasal medium supplemented with B27, Glutamax, and 1%
penicillin/streptomycin (Life Technologies). At 5 days in vitro (DIV), neurons were transfected
with cDNA encoding green fluorescent protein (GFP) in the pEGFP-C1 vector (Clontech) using
Lipofectamine 2000 (Invitrogen). GFP is expressed throughout the entire neuron and ensures
accurate assessment of dendrite number. At 7 DIV, immunostaining was performed to enhance
the natural fluorescence of GFP. Neurons were fixed in 4% paraformaldehyde (PFA) in phosphate
buffered saline (PBS), after which they were incubated in blocking buffer. Primary antibody
incubation (1:1000 dilution of rat anti-GFP from Dr. Shu-Chan Hsu of Rutgers University) occurred
at 4˚C overnight. Coverslips were washed 3 times with PBS and then incubated with secondary
antibody (1:250 dilution of Cy2-anti rat IgG from Jackson Immunoresearch) for 1 hour at room
temperature. Coverslips were washed twice more with PBS and then incubated with Hoechst for
5 min at room temperature to stain the nuclei. Coverslips were washed a final time with PBS and
were then mounted onto glass microscope slides using Fluoromount (Southern Biotechnology).
Transfected cells were imaged using an Olympus Optical IX50 microscope with a Cooke SensiCam
charge-coupled device (CCD) cooled camera fluorescence imaging system and ImagePro software
(Media Cybernetics). All images were taken at 200x magnification.
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Images were processed as previously described [47, 48], using customs scripts written in Matlab
(MathWorks). Briefly, cell bodies and dendrites were traced in ImageJ using the NeuronJ plugin
(NIH, Bethesda, MD). The data were exported to NeuronStudio and checked to ensure proper
connectivity of dendrites. Sholl analysis was then performed at 6 μm intervals starting at 0 μm
from the soma using the Bonfire program [47, 48].
2.2

Discrete statistical model for neural growth without restriction
2.2.1 Recurrence formulas for the probability distribution of all possible neural trees

The results from the previous section can be proven using the discrete probability distribution
function at any time step N, with 𝑝 as the branching probability and q is the elongation
probability. The evolution of all possible trees may be described using a recursive function
𝑓𝑛 (𝑝, 𝑞) as follows: For the first step (step 0), use f0(p, q) = 1 to denote a single branch (see Table
1, step 0). At step 1, 𝑓1 (𝑝, 𝑞) = 𝑝 + 𝑞, (see Table 1, step 1), indicates the existence of two trees:
the first with two active branches and probability of instantiation p, and the second containing a
single branch and instantiated with probability q. Note that since 𝑝 + 𝑞 = 1, the sum of all
probabilities adds up to 1, as needed. At step 2, we can describe the existing trees using
𝑓2 (𝑝, 𝑞) = 𝑞 ∗ 𝑝 + q ∗ q + p ∗ (p2 + 2 p q + q2 ) = (q + p(p + q)) ∗ (p + q).
These trees can be identified in the tree evolution (Figure 1) for steps 1-2, and are listed in Table
1 for step 2. A summary figure is listed in Figure 3.
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Figure 3 Summary figure for the evolution of the trees for the first three time steps.
The number of terminal branches is listed for each tree, followed by the probability of obtaining
that particular outcome starting from the previous step. The overall probability of a certain
outcome can be obtained by multiplying the probabilities along the path.

Intuitively, the single-branch tree can evolve on two possible paths (extend or branch) as
indicated by the first two terms. The tree with two terminal branches can generate trees with 4,
3 and 2 terminal branches, respectively. The formula for step 3, 𝑓2 (𝑝, 𝑞), can now be obtained
by substituting 𝑝 by 𝑝 ∗ (𝑝 + 𝑞) in formula 𝑓1 (𝑝, 𝑞) and multiplying the result with (𝑝 + 𝑞).
We thus hypothesize the following recurrence formula for generating all trees at step n:
𝑓𝑛+1 (𝑝, 𝑞) = 𝑓𝑛 (𝑝 ∗ (𝑝 + 𝑞), 𝑞) ∗ (𝑝 + 𝑞)

(5)

A proof of this formula is provided in the next section. This explicit recursive description of the
discrete probability distribution now allows us to compute the expected number of mean
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branches and the associated variance in the general case, extending the enumerative example
shown in Table 1. As a result, when the number of steps is small enough such that all trees have
total lengths below the maximum allowed value (i.e. before they run out of resources and cannot
extend anymore), we can prove that the expected mean indeed follows the general formula
𝐸(𝑛) = (1 + 𝑝)𝑛 . Furthermore, we were able to derive a recurrence formula that described the
associated variance:
𝑉𝑎𝑟(𝑆𝑛 ) = 𝑝 ∗ (1 − 𝑝) ∗ (1 − 𝑝)𝑛−1 ∗ 𝑔(𝑛)

(6)

where𝑔(𝑛 + 1) = 𝑝 ∗ 𝑔(𝑛) + 𝑔(𝑛) + 1, with 𝑔(1) = 1
This has the following solution:
Varn (X) = (1 + p)2∗(n−1) ∗ (1 − p2 ) + (1 + p)n−1 ∗ (p − 1) n = 1,2, … …

(7)

2.2.2 Derivation of the recurrence formula for all possible neuronal trees
We now prove the formula for generating all trees: 𝑓𝑛+1 (𝑝, 𝑞) = 𝑓𝑛 (𝑝. (𝑝 + 𝑞), 𝑞). (𝑝 + 𝑞). We
𝑛

−1 𝑘
write the formula for step n as 𝑓𝑛 (𝑝, 𝑞) = ∑2𝑘=1
𝑝 𝑔𝑘 (𝑞) where 𝑔𝑘 (𝑞) are polynomials in q.

Obviously, this is true for the first 3 time steps considered in Table 1. Each individual term in
the𝑓𝑛 (𝑝, 𝑞), of the form 𝑝𝑘 𝑔𝑘 (𝑞) represents the probability of generating a tree with 𝑘 + 1
active branches. Some of the trees are isomorphs, for simplicity that will be absorbed into the
coefficients from𝑔𝑘 (𝑞). In order to derive the general formula for 𝑛 + 1 step, we note that the
trees that contain a 𝑝𝑘 term have k + 1 terminal or active branches (see Table 1). Then, at the
next step, these active branches can generate between 0 and (𝑘 + 1) new active branches.
Taking into account the degeneration (isomorph trees), the probabilities for these new branches
are described by the combinations from the (𝑝 + 𝑞)𝑘+1 formula. We then obtain the following:
2𝑛 −1

2𝑛 −1

𝑓𝑛+1 (𝑝, 𝑞) = ∑ 𝑝𝑘 (𝑝 + 𝑞)𝑘+1 𝑔𝑘 (𝑞) = (𝑝 + 𝑞) ∑ 𝑝𝑘 (𝑝 + 𝑞)𝑘 𝑔𝑘 (𝑞)
𝑘=1

𝑘=1
2𝑛 −1

= (𝑝 + 𝑞) ∑ (𝑝(𝑝 + 𝑞))𝑘 𝑔𝑘 (𝑞) = (𝑝 + 𝑞)𝑓𝑛 (𝑝, 𝑞)
𝑘=1
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This proves the validity of formula of mean and variance.

2.2.3 Derivation for the expected number at distance k: 𝑷(𝒏) = (𝟏 + 𝒑)𝒏
We want now to prove that the expected number of branches at step n is (1 + 𝑝)𝑛 . In order to
achieve this, we need to prove the following intermediary steps. First, we can determine the
expected number of active branches at step 𝑛 as the derivative of the 𝑓𝑛 ∗ 𝑝 function: (𝑓𝑛 (𝑝, 𝑞) ∗
𝑝)’, where the symbol ’ stands for derivative with respect to p. Since the terms in the sum of
𝑓𝑛 (𝑝, 𝑞) are all the entries in the global probability table, we now have the expected number of
active branches at time step n (and distance 𝑛 + 1 away from the origin):
𝐸(𝑛𝑢𝑚𝑏𝑒𝑟 𝑎𝑐𝑡𝑖𝑣𝑒 𝑏𝑟𝑎𝑛𝑐ℎ𝑒𝑠 𝑎𝑡 𝑠𝑡𝑒𝑝 𝑛) = 𝐸(𝑏𝑛 )
=

∑

𝑛𝑢𝑚𝑏𝑒𝑟 𝑎𝑐𝑡𝑖𝑣𝑒 𝑏𝑟𝑎𝑛𝑐ℎ𝑒𝑠 𝑜𝑛 𝑡𝑟𝑒𝑒 ∗ 𝑡𝑟𝑒𝑒 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦

𝑘=𝑎𝑙𝑙 𝑡𝑟𝑒𝑒𝑠

We rewrite this to be:
2𝑛 −1

𝑓𝑛 (𝑝, 𝑞) = ∑ 𝑝𝑘 𝑔𝑘 (𝑞)
𝑘=1

We now obtain the following:
𝐸(𝑏𝑛 ) =

∑

𝑛𝑢𝑚𝑏𝑒𝑟 𝑎𝑐𝑡𝑖𝑣𝑒 𝑏𝑟𝑎𝑛𝑐ℎ𝑒𝑠 𝑜𝑛 𝑡𝑟𝑒𝑒 ∗ 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑦 𝑡𝑟𝑒𝑒

𝑘=𝑎𝑙𝑙 𝑡𝑟𝑒𝑒𝑠
2𝑛 −1

𝑛

′

𝑛

′

= ∑ (𝑘 + 1)𝑝𝑘 𝑔𝑘 (𝑞) = (∑ 𝑝𝑘+1 𝑔𝑘 (𝑞)) = (𝑝. ∑ 𝑝𝑘 𝑔𝑘 (𝑞))
𝑘=0

𝑘=1

= (𝑝. 𝑓𝑛+1 (𝑝, 𝑞))

𝑘=1

′

Using these intermediary results, the expected number of branches evaluates as (1 + p)n, as
proved by induction below.
𝐸(𝑏𝑛 ) = (1 + 𝑝)𝑛
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′

2𝑛 −1

′

2𝑛 −1

𝐸(𝑏𝑛 ) = (𝑝. 𝑓𝑛+1 (𝑝, 𝑞))′ = (𝑝. ∑ 𝑝𝑘 (𝑝 + 𝑞)𝑘+1 𝑔𝑘 (𝑞)) = ( ∑ 𝑝𝑘+1 (𝑝 + 𝑞)𝑘+1 𝑔𝑘 (𝑞))
𝑘=0

𝑘=0
′

2𝑛 −1

2𝑛 −1

= ( ∑ (𝑝. (𝑝 + 𝑞))𝑘+1 𝑔𝑘 (𝑞)) = ∑ (𝑘 + 1)(2𝑝 + 𝑞)(𝑝. (𝑝 + 𝑞))𝑘 𝑔𝑘 (𝑞)
𝑘=0

𝑘=0

2𝑛 −1

= ∑ (𝑘 + 1)(1 + 𝑝)(𝑝. (𝑝 + 𝑞))𝑘 𝑔𝑘 (𝑞)
𝑘=0
2𝑛 −1
𝑘

= (1 + 𝑝) ∑ (𝑘 + 1)(𝑝. (𝑝 + 𝑞)) 𝑔𝑘 (𝑞)
𝑘=0
2𝑛 −1
′

= (1 + 𝑝) ∑ (𝑘 + 1)(2𝑝 + 𝑞)𝑝𝑘 𝑔𝑘 (𝑞) = (1 + 𝑝)(𝑝. 𝑓𝑛 (𝑝, 𝑞)) = (1 + 𝑝)𝑛+1
𝑘=0

Furthermore, we can extend this approach and compute the variance for this expected number,
using 𝑣𝑎𝑟(𝑋) = 𝐸(𝑋 2 ) – 𝐸(𝑥)2 = ((𝑓𝑛 (𝑝, 𝑞) ∗ 𝑝)’ ∗ 𝑝)’ – ((1 + 𝑝)𝑛 )2
After simplifications, this can also be written as a recursion formula:
𝑉𝑎𝑟(𝑆𝑛 ) = 𝑝. (1 − 𝑝). (1 − 𝑝)𝑛−1 . 𝑔(𝑛)
𝑔(𝑛 + 1) = 𝑝. 𝑔(𝑛) + 𝑔(𝑛) + 1
𝑔(1) = 1
After solving this difference equation, we obtain the solution for the general formula of the
variance:
Varn (X) = (1 + p)2(n−1) . (1 − p2 ) + (1 + p)n−1 . (p − 1) n = 1,2,
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2.3

Neural Growth Model with Restrictions
2.3.1 Optimal targeting region for trees with size restrictions

At larger distances from the origin, some trees should be eliminated from the analysis. For
example, if the maximum length of the tree is equal to 7, the larger trees will not generate any
additional subtrees after time step 3. However, the smaller ones do, and the formulas for the
number of searching sites at distance n that allow for a tree of maximum size 7 are the following:
Table 1 List of the trees that can be generated when maximum length of the tree is equal to 7.
Step 1

𝑝 + 1

enough resources

Step 2

(𝑝 + 1)2

enough resources

Step 3

(𝑝 − 1)2 ∗ (2 ∗ 𝑝3 + 5 ∗ 𝑝 + 1)

some trees are eliminated

Step 4

−(𝑝 − 1)3 ∗ (− 2 ∗ 𝑝2 + 3 ∗ 𝑝 + 1)

some trees are eliminated
the one that does not branch at all

Step 5

(𝑝 − 1)4 ∗ (𝑝 + 1)

and the one that branches after 4
steps

Step 6

only the tree that does not branch

(𝑝 − 1)6

at all reaches this far

2.3.2 Right tail series expansion up to order 𝒑𝟑
𝑓(𝑁−𝑘)

The series expansion for the right tails follows the formula 𝑓(𝑛−𝑘+1) = 𝑓1 (𝑘) ∙ 𝑝 + 𝑓2 (𝑘) ∙ 𝑝2 +
𝑓3 (𝑘) ∙ 𝑝3 + ⋯ = ∑𝑘𝑗=1 𝑓𝑗 (𝑘) ∙ 𝑝 𝑗 , where the fj functions are defined below:
𝑓1 (0) = 𝑞 𝑁 , 𝑓2 (0) = 0, 𝑓3 (0) = 0, 𝑓4 (0) = 0
𝑓1 (1) = 𝑞 𝑁−1 , 𝑓2 (1) = 2𝑝𝑞 𝑁−2 , 𝑓3 (1) = 0, 𝑓4 (1) = 0, 𝑓1 (𝑘) = 𝑞 𝑁−𝑘
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𝑓2 (2) = 2𝑝𝑞 𝑁−2 + 2𝑝𝑞 𝑁−3 , 𝑓3 (2) = 0, 𝑓4 (2) = 0
𝑘

𝑓2 (𝑘) = 2𝑝𝑞

𝑁−2

∑ 𝑝𝑖−𝑘 , 𝑓3 (2) = 0, 𝑓4 (2) = 0
𝑖=1

𝑓3 (3) = 6𝑝2 𝑞 𝑁−4 , 𝑓4 (3) = 0
𝑓3 (4) = 6𝑝2 𝑞 𝑁−4 + 6𝑝2 𝑞 𝑁−4 , 𝑓4 (4) = 4𝑝3 𝑞 𝑁−6
𝑘

𝑓3 (𝑘) = 6𝑝2 𝑞 𝑁−4 ∑ 𝑔(𝑖)𝑝𝑖−𝑘
𝑖=3

𝑔(0) = 𝑔(1) = 𝑔(2) = 0, 𝑔(3) = 1, 𝑔(4) = 1, 𝑔(5) = 2, 𝑔(𝑘) = 𝑔(𝑘 − 2) + 1
𝑘

𝑓4 (𝑘) = 4𝑝3 𝑞 𝑁−6 ∑ ℎ(𝑖)𝑝𝑖−𝑘
𝑖=5

ℎ(0) = ℎ(1) = ℎ(2) = ℎ(3) = ℎ(4) = 0, ℎ(5) = 1, ℎ(6) = 1, ℎ(7) = ℎ(5) + 6 = 7
ℎ(8) = ℎ(6) + 7 = 8, ℎ(9) = ℎ(7) + 7 = 14
ℎ(3𝑗 + 4) = ℎ(3𝑗 + 2) + 6𝑗
ℎ(3𝑗 + 5) = ℎ(3𝑗 + 3) + 6𝑗 + 1
ℎ(3𝑗 + 6) = ℎ(3𝑗 + 4) + 6𝑗 + 1

Therefore, up to the 4th order approximation in p we have:
𝑅(𝑁 − 𝑘) =

𝑓(𝑘 + 1) 𝑓1 (𝑘 + 1) + 𝑓2 (𝑘 + 1) + 𝑓3 (𝑘 + 1) + 𝑓4 (𝑘 + 1)
=
𝑓(𝑘)
𝑓1 (𝑘) + 𝑓2 (𝑘) + 𝑓3 (𝑘) + 𝑓4 (𝑘)

𝑅(𝑁 − 𝑘)
𝑖−𝑘
𝑖−𝑘
𝑖−𝑘
𝑞 𝑁−(𝑘+1) + 2𝑝𝑞 𝑁−2 ∑𝑘+1
+ 3𝑝2 𝑞 𝑁−4 ∑𝑘+1
+ 4𝑝3 𝑞 𝑁−6 ∑𝑘+1
𝑖=1 𝑝
𝑖=3 2𝑔(𝑖)𝑝
𝑖=5 ℎ(𝑖)𝑝
=
𝑞 𝑁−𝑘 + 2𝑝𝑞 𝑁−2 ∑𝑘𝑖=1 𝑝𝑖−𝑘 + 3𝑝2 𝑞 𝑁−4 ∑𝑘𝑖=3 2𝑔(𝑖)𝑝𝑖−𝑘 + 4𝑝3 𝑞 𝑁−6 ∑𝑘𝑖=5 ℎ(𝑖)𝑝𝑖−𝑘

Table 2 Coefficients of first 3 orders from the proportions between steps of an example with
26 steps.
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𝑆𝑡𝑒𝑝 (𝑁 − 1)𝑡ℎ
𝑆𝑡𝑒𝑝 𝑁𝑡ℎ

Coefficient of 1st order

Coefficient of 2nd order

Coefficient of 3rd order

N = 26

3

5

7

N = 25

3

-1

3

N = 24

3

-1

17

N = 23

3

-7

47

N = 22

3

-7

55

N = 21

3

-13

135

N = 20

3

-13

141

2.3.3 Determining the approximation for the peak location
We can use this table 2 to derive a better, second order approximation that improves the first
order approximation derived in formula (3), namely 𝑘 =

3+5𝑝
6𝑝

. Similar to the derivation of this

equation, the exact location where the ratio becomes 1 can be used to approximate where the
spatial location of the peak of the distribution occurs. This occurs at step N – k, when

𝑃(𝑁−𝑘−1)
𝑃(𝑁−𝑘)

,

which starts with an initial value of (1 + 3𝑝 + 5𝑝2 + 𝑓3 (𝑘)𝑝3 ) , reaches a value of 1 after
experiencing continuous decreases in value. This is determined by:
1 + 3𝑝 + (5 – 6𝑘)𝑝2 + 𝑓3 (𝑘)𝑝3 = 1
which can be easily rewritten as
3 + (5 – 6𝑘)𝑝 + 𝑓3 (𝑘)𝑝2 = 0
which can only be solved numerically in 𝑘 due to the complicated expression for the function
𝑓3 (𝑘).
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The condition that all neurite tips reach a target distance D translates to:
𝐷 = 𝐿0 𝑁𝑚𝑎𝑥

= 𝐿0 log 2 (1 +

𝐿𝑚𝑎𝑥
)
𝐿0

Now we can set up the comparison: using the geometrical series result, we determine that the
average number of branches at time step 𝑘 is (1 + 𝑝)𝑘 , and therefore we obtain the total length
of the tree after completion of n steps:
𝑛
2

𝑛

1 + (1 + 𝑝) + (1 + 𝑝) + ⋯ + (1 + 𝑝) = ∑(1 + 𝑝)𝑘 =
𝑘=0

(1 + 𝑝)𝑛+1 − 1 (1 + 𝑝)𝑛+1 − 1
=
1+𝑝−1
𝑝

Setting up the condition that the tree stops expanding when it reaches maximal allowed length
L, we get:
𝐿=

(1 + 𝑝)𝑛+1 − 1
𝑝

We can now compute p from this equation: 𝑝 ⋅ 𝐿 = (1 + 𝑝)𝑛+1 − 1, or equivalently 1 + 𝑝 ⋅ 𝐿 =
(1 + 𝑝)𝑛+1 Taking log on both sides: ln(1 + pL) = (𝑛 + 1)ln(1 + 𝑝), or equivalently 𝑛 + 1 =
ln(1+𝑝𝐿)
ln(1+𝑝)

. We finally obtain:

𝑛=

ln(1 + 𝑝𝐿)
−1
ln(1 + 𝑝)

Note that when p → 0, the single-branch tree expands all the way to x = N (in N - 1 time steps)
since
ln(1 + 𝑝𝐿)
𝑙𝑛′ (1 + 𝑝𝐿)
′
′
lim 𝑛 = lim (
− 1) = 𝐿 𝐻𝑜𝑠𝑝𝑖𝑡𝑎𝑙 𝑠 𝑅𝑢𝑙𝑒 = lim ( ′
)−1
𝑝→0
𝑝→0 ln(1 + 𝑝)
𝑝→0 𝑙𝑛 (1 + 𝑝)
𝐿
1 + 𝑝𝐿
= lim (
)−1 =𝐿−1
1
𝑝→0
1+𝑝
Because the probability of this tree is 𝑓(𝑝) = (1 − 𝑝)𝑁−1 , the function f is obviously maximized
at 𝑝 = 0. Not surprisingly, the symbolic/numeric evaluation yields the same result. At the other

26

end of the spectrum, when p → 1, the tree expands as 1 + 2 + 4 + 8 + 16 + … = 𝑁 and
runs out of resources. As an example, when 𝐿 = 32, we obtain:
𝑛=

ln(1 + 1𝐿)
ln(1 + 𝐿)
−1=
− 1 = 𝑙𝑛2 (1 + 𝐿) − 1 = 𝑙𝑛2 (1 + 31) − 1 = 5 − 1 = 4
ln(1 + 1)
ln(2)

These results assume that the number of tree branches doubles without fail at each time step
until the tree will finally run out of resources. At that point, the number of terminal branches
will be maximal, meaning that the tree peaked at the right location and it will have the highest
chance to find a target in this blind search there. Note that in contrast to previous results, what
we seek here is the optimal branching probability that would allow this to happen. The
optimization problem here first selects the distance at which maximal performances are sought,
then the uniform branching probability is determined.

2.4

Tumor Growth Models
2.4.1 Materials and methods for predicting tumor growth rate

Patients: A total of 114 patients were derived from the database of screen-detected primary
breast carcinoma patients presented to Nottingham City Hospital (UK) from 1988 to 2008 with
interval cancer, and for whom revision of the previous screening mammography showed a
previously undetected cancer at the same affected site, all the data was used with permission
from our collaborators. This misdiagnosis might be due to a minimal visible diagnosis in the
previous mammogram. The maximum tumor dimension identified by the mammography was
available for each case. We excluded cases presented with predominant calcification. All the
clinicopathological information was available for 92 patients. For each case, information relating
to changes in tumor size between the time of screening and of diagnosis as well as the dates of
screening and diagnosis was used to estimate tumor growth rate. Clinical and pathological data
of the patients including age, histological tumor type, primary tumor size, lymph node status,
histological status, NPI and vascular invasion were obtained in a standard manner at the time of
diagnosis was compiled.
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Calculated Tumor volume: The two measurements in the mammogram screening were assumed
as tumor diameter and tumor height. The highest mammogram reading was assumed as height
4

and the other as diameter to calculate the volume using the formula 3 𝜋𝑎𝑏 2 (assuming the tumor
to be ellipsoidal). The measured tumor height was introduced into the formula in the position b
after dividing by 2 whereas the tumor diameter was introduced in the position of 𝑎 after dividing
by 2. We simply used the formula
4
𝑇𝑢𝑚𝑜𝑟 𝑉𝑜𝑙𝑢𝑚𝑒 = 𝜋𝑎𝑏 2
3
to calculate the tumor volume at the time of diagnosis and tumor volume at the time of
screening to determine the change in volume.

Figure 4 Ellipsoid Tumor
Ellipsoid tumor calculated by tumor diameter and tumor height with the formula 4/3 πab2. Graph reproduced
from Richtig study [80].

2.4.2 Model selection for growth rate
As described in the introduction part, we have three models to calculate the growth rate. And
based on the results, we choose the Exponential model, which provides the best result from
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survival analysis, more results will be shown in the Result section 3.4.2.
Growth Rate from Linear Model

Growth Rate from Exponential
Model
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Figure 5 Histogram of individual growth rate from three models
Figure 5 shows the histogram of growth rate from three models. (a) is from the linear model
which gives most skewed results, which is not useful for further study. (b) and (c) are from the
exponential model and the logistic model, both of which are less skewed. The plot for (c) however
shows that there are more outliers from the third model. Since (b) is closer to a bell shaped
distribution, we choose it for further studies.

Calculated Tumor Growth Rate:
𝛼=

log(𝑉𝑜𝑙𝑢𝑚𝑒𝑡 ) − log(𝑉𝑜𝑙𝑢𝑚𝑒𝑡0 )
𝑡 − 𝑡0
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Where,
𝑉𝑜𝑙𝑢𝑚𝑒𝑡 is volume at time of diagnosis calculated as:
𝑉𝑜𝑙𝑢𝑚𝑒𝑡 = 𝑉𝑜𝑙𝑢𝑚𝑒𝑡0 ∗ 𝑒 𝛼(𝑡−𝑡0)
𝑉𝑜𝑙𝑢𝑚𝑒𝑡0 is volume at time of screening. 𝑒 𝑡−𝑡0 is an exponential function with 𝛼 being growth
rate and 𝑡 − 𝑡0 is the time difference between screening and diagnosis.
2.4.3 Biomarkers in the model
Immunohistochemistry: For each patient, a representative formalin-fixed paraffin waxembedded tumor block was obtained from the Nottingham breast tumor bank. 4 μm thick fullface sections were prepared and placed onto glass slides (Xtra®, Surgipath).
ER, PR, HER2, CK5/6, Ki67, BCl2, and MCM2 staining: We applied IHC to FFPE tissue sections using
Novolink™ Max Polymer Detection System from Leica Biosystems (Leica, Newcastle, UK). Heatinduced retrieval of antigen epitopes was performed in citrate buffer (pH 6) using a microwave
for 20 minutes, followed by immediate cooling. The slides were rinsed with Tris Buffered Saline
(TBS, pH 7.6). The primary antibody was applied for 30 minutes at room temperature. Optimal
antibody dilutions have based on a study by El Rehim et al, (2005). Dako® Antibody Diluent (ref
# 50809, let # 10032882) was used. To visualize antibody binding, 3-3’ Diaminobenzidine
tetrahydrochloride (Novolink DAB substrate buffer plus) was freshly prepared and used as a
chromogen. The tissue sections were counter stained with Mayer’s hematoxylin for 6 minutes.
Slides were dehydrated in alcohol, cleared in Xylene then mounted with DPX.
Cleaved Caspase-3 Staining: This marker was stained for using a pre-fabricated detection kit
(SignalStain® Cleaved Caspase-3 (Asp175) IHC Detection Kit #8120, Cell Signaling Technology)
following manufacturer’s instructions. As before, slides were de-waxed and rehydrated before
antigen retrieval was carried out. Pre-diluted cleaved caspase-3 Primary Antibody (# 9661, clone
D175, polyclonal rabbit) was applied and incubated overnight at 4°C ensuring they did not dry
out. Following incubation, prediluted Biotinylated Secondary Antibody was applied. Slides were
closely monitored after the application of NovaRedTM Substrate Chromogen solution and were
immersed in dH20 when red-brown staining was observed (typically after approximately 7-8
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minutes). They were counterstained with Haematoxylin for 6 minutes, dehydrated in denatured
ethanol and xylene as before, before mounting with cover slips.
Assessment of IHC staining:
For each slide, only the invasive tumor component was scored. Cases were scored twice using
light microscopy; the second time blind to the first results. Scores were then averaged. The cases
were scored without the prior knowledge of patients’ clinicopathological data. For ER and PR
nuclear immunoreactivity, H-Score was employed. An H-score of 10 was used as the cut-off, in
accordance with normal clinical practice at Nottingham.
For HER-2, overall membranous staining intensity was scored on a 0-3 basis using guidelines by
the American Society of Clinical Oncology and College of American Pathologists, with 0
representing no visible staining, and 3 representing extremely intense membranous staining.
For Ki67, only nuclear immunoreactivity of proliferating cells was recorded, whilst for cleaved
Caspase-3, only cells undergoing apoptosis were noted. For both markers, the invasive tumor
component in each case was scanned until the staining “hot-spot” was identified. At 40x
magnification, the number of cell nuclei stained regardless of staining pattern or intensity per
1000 invasive tumor cells was then counted. The % staining in the “hot-spot” field was then
calculated.
CK5/6 was scored as the overall percentage of positively staining cells within the whole invasive
tumor component. For the purposes of this study, and based previous studies a cut-off of 10%
staining was used to distinguish between positive and negative expression groups. Breast cancer
molecular subtypes were defined based on their IHC expression profile for ER, PgR, HER2, CK5/6
into1) luminal (ER+ and/or PR+ /HER2-), 2) HER2+ (HER2 positive), 3) Triple negative (TN; ER-, PR-,
HER2-) and Basal-like Breast cancer (BLBC: TN+ CK5/6 +). [50]
2.4.4 Statistical analysis on the growth rate
All the statistical analysis in this paper was performed using Statistical Analysis System (SAS 9.4,
Cary, North Carolina, US). For the following analysis, P-value less than 0.05 were taken as
significant, for both one-tailed tests and two-tail tests. Spearman’s Rank-Order Correlations were
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used to test the correlation between the growth rate and each biomarker. We also apply Fisher’s
exact test on the contingency table to examine the association between type of breast cancer
and each biomarker. To compare the growth rate among patients with different levels of
biomarkers, we did the analysis of variance (ANOVA) on the biomarkers, which are associated
with growth rate determined by Spearman’s Rand-Order correlation test. At last, Multivariate
Cox Proportional Hazard Model was fitted with growth rate and potential confounders selected
from the previous analysis, in order to determine the effect of a unit increment in the growth
rate on the change of hazard rate.
2.4.5 Choose the cut point for growth rate
In order to find the optimal cut point, we first have a set of possible of candidates and then
choose the best one based on the results of dichotomizing the patients with different
performances. The maximum number of candidate cut points is k- 1, where k is the number of
unique values in the data of that continuous covariate. Some researchers have suggested
excluding the outer 10-20% of the continuous covariate distribution to avoid having small
numbers in one of the groups the following dichotomization, thereby preventing substantial
losses in statistical power [39]. The inner 80-90% of the distribution from which a cutpoint is
chosen is referred to as the selection interval. For each candidate cutpoint within a specified
selection interval, an appropriate two-sample test with concomitant test statistic and p-value (Pc)
is determined. A cutpoint model may be appropriate if any 𝑃𝑐 is less than or equal to some
allowable level of Type I error. The optimal cutpoint is often defined as that candidate cutpoint
with the smallest Pc. This method for estimating a cutpoint is referred to as the minimum p-value
approach, or alternatively the maximum statistic approach. Other criteria for choosing an optimal
cutpoint have been suggested, including maximum effect size and the maximum precision of
estimates, but have received less support.
We first choose all possible candidates of cutpoints, then we calculated the p-values from logrank test [51]. Each log-rank test is trying to test the hypothesis that the survival curves of two
groups are the same. Then the cutpoint with the lowest p-value is the one that split the covariates
best.
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After I find the optimal cutpoint, I used SAS proc lifetest to test the efficiency of separating the
patients into two distinct groups with different level of risk to death. First, the survival curve is
estimated by Kaplan-Meier method.
Then, in order to test the difference between the risks to death of two groups, I used log-rank
test which is well known and widely used [52]. It is used to test the null hypothesis that survival
curves of two populations have no significant difference. The test statistic is calculated as follows:
𝜒

2 (log

(𝑂1 − 𝐸1 )2 (𝑂2 − 𝐸2 )2
𝑟𝑎𝑛𝑘) =
+
𝐸1
𝐸2

Where the 𝑂1 and 𝑂2 are the total numbers of observed events in group 1 and 2, respectively,
and 𝐸1 and 𝐸2 the total number of expected events. The total expected number of events for a
group is the sum of the expected number of events at the time of each event. The expected
number of events at the time of an event can be calculated as the risk to death at that time
multiplied by the number alive in the group. Under the null hypothesis, the risk to death can be
calculated from the combined data for both groups.
2.4.6 Fitting the logistic regression model to predict growth rate
In order to build up model to predict the growth rate, we fitted a logistic regression model with
patient’s biomarker. Here we used backward model selection method to choose the best model
for the future use, which has been done with following steps:
Variable transformation: Our prognostic data include different types of variables, such as strings,
numeric and symbolic. Before we use them in the model, we transformed them into proper form
based on both statistical and clinical reasons. From the statistical perspective, all variables that
have potential problem of multicollinearity and non-normality must be transformed, by either
factorized or scaled. From the clinical perspective, we need to transform variables in order to
make them easy to be used in the future implementation.
Step-wise model selection: We put all variables in the model in the beginning and calculate all
the statistics of the model, such as R-squared, AIC, ANOVA, and so on. Then, based on the
significance of the coefficients, we eliminated the least influencing variable from the model and
33

calculated the statistics again. We kept doing this until obtaining a model with all significant
variables.
Cross validation: In order to make our model robust for new data, we used cross-validation
method to assess our model. We choose 80% of the data to be the training data, with 20% of the
data to be the validation set. The best model is the one not only works well for training data, but
also works well for the validation set.

2.5

Extending survival analysis on the recurrence of breast cancer
2.5.1 Cohort study

In this study, a large cohort of breast cancer patients treated at Northside Hospital (NH) in Atlanta,
Georgia from 2005 to 2015, were examined, all data was used with permission from our
collaborator Ritu. We received approval and permission by the institutional review board at
Northside Hospital to access patient clinico-pathological information used in this study and have
a written human subject’s assurance on file. The demographics and clinico-pathological
characteristics of each patient were recorded to generate a database of 10,504 patients. Patient
demographic information recorded in the database included age at the time of diagnosis and
ethnicity. Age at diagnosis among patients was divided into three subgroups, comprised of
patients below the age of 48 (premenopausal), over the age of 55 (postmenopausal), and in
between (premenopausal), to precisely describe menopausal status. The races of patients in the
database were primarily comprised of African-Americans (AA) and European-Americans (EA). The
“unknown/others” subcategory denote patients of all other ethnicities (excluding AA and EA) and
patients lacking race information. Ethnicity was reported according to the patient’s claim. Breast
tumor characteristics that were recorded for each patient consisted of nuclear grade,
Nottingham (NGH) grade, stage, nodal status, T (primary tumor), N (lymph node metastasis) and
M (distant metastasis) classifications. The 7th edition of the American Joint Committee on Cancer
(AJCC)/Union for International Cancer Control (UICC) TNM Classification and Stage groupings for
breast carcinoma was used in this article. All patient treatments were recorded, including
chemotherapy, hormone, and radiation therapy. Patients that underwent chemotherapy were
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subcategorized into neoadjuvant and adjuvant depending on the timing of treatment.
Additionally, any combination of the hormone, radiation, and chemotherapy that patients
received was labeled as a combination of adjuvant therapies. Follow-up data was collected to
determine breast cancer recurrence episodes, as well as the site of recurrence, such as local,
regional or distant sites. Local recurrences comprise recurrence of the tumor in the primary site.
Regional recurrence encompasses recurrence of the breast cancer in adjacent lymph nodes.
Distant recurrences involve metastatic breast cancer in remote organs such as distant lymph
nodes, bone, liver or others.
2.5.2 Follow up
Both follow-up of patients and initial diagnosis occurred between the years of 2005 and 2015.
Initial diagnosis dates, as well as treatment start and completion dates for any therapies, were
documented. Dates of the last contact for all patients were recorded. Survival status (alive/dead)
was reported for each patient along with survival time. Dates of the first recurrence were noted.
February 19, 2015, was the final follow-up for the last patient seen.
2.5.3 Statistical Analysis
A significance level of 0.05 and 95% confidence intervals were selected for all analyses. Sample
sizes were based on the available patients that comprised each category in the NH database and
not power analysis. Chi-square tests were performed to examine significant differences in clinicopathological characteristics, therapy administration, and recurrence characteristics between
recurrence and non-recurrence patients as well as between AA and EA breast cancer patients.
Recurrence rates were calculated as per 1000 person-years (incidence rate) from the date of
diagnosis until the first incidence of recurrence over a 10-year period irrespective of specific
treatment and for each form of treatment administered. Recurrence was identified as tumors
that either reformed from the primary tumor or cells that metastasized from the primary site and
colonized at a distant site. Test statistics were computed using MATLAB (MATLAB and Statistics
Toolbox Release 2015a, The MathWorks, Inc., Natick, Massachusetts, United States) program and
1-tailed univariate p-values were reported. The one-tailed analysis was preferred over two-tailed
for this particular study to adequately reflect the presumption that treatment is expected to
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improve patient outcome. Multivariate Cox proportional hazard models were computed to
determine significant differences in recurrence rates and patterns between the racial groups (6,
7). These statistical models were additionally modified to control for variables of age, grade, and
stage. The Kaplan-Meier analysis was conducted in SAS 9.4 program to estimate survival function
for AA and EA with the recurrent disease over a 10-year period from the time of first tumor
reappearance until death or end of follow-up. A log-rank test was conducted to evaluate
significance level for between-race differences in survival. Finally, a t-test was used to compare
mean time from first recorded recurrence event until death among patients with distant
recurrence.
In order to extend the survival analysis on the recurrence of breast cancer, we borrowed the
concept of time to death and applied on the time to recurrence. Then instead of risk to death,
now we can compare the risk to recurrence among different groups.
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3
3.1

RESULTS

Discrete Model
3.1.1 Unrestricted neural growth model

In this study, we used a simplified stochastic model to investigate how changes in branching
probability influence a neuron’s success in targeting locations that differ in distance from the
initiation point. Since our model aims to mimic experimental results that occur in laboratory
tissue growth, we assume that each neuron performs a blind search in their quest to connect to
the other neurons, and as such, it cannot benefit from the chemical cues that exist during normal
development. Therefore, success in finding a target within a certain region depends on the
number of active branches that reach that portion of space. The rules for generating a simplified
neuronal tree, described in our previous work [2], are as follows. Initially, there is one active
branch that at each discrete time step can branch into two neurites with probability p or further
extend with probability𝑞 = 1 − 𝑝. Furthermore, each active branch then acts independently
of the others and can further extend or branch out to create one additional new neurite. We
only account for an extra neurite because we can make sure that the probability to create more
than two branches is too small to be included in our model, by choosing small enough time
intervals. As a result, multiple branching processes shape the structure of the resulting neuronal
tree in a random fashion. While in our previous work each branch is allowed to evolve
stochastically in space, here we ignore the spatial structure of these branches and assume that
they evolve linearly after branching at small angles to facilitate the statistical estimates for the
resulting probability distribution. This simplification allows us to obtain analytical results while
taking into account the most important feature of the stochastic neuronal tree, namely the
random generation of extra neurites. The advantage of this approach is that for each step, we
can generate the full probability distribution for each possible outcome. An illustration for all
possible outcomes is shown in Figure 6 for the first three time steps, reproduced from [2].
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Figure 6 Diagram of all possible tree instantiations after 3 time steps.
The full population distribution can be generated by examining all possible tree configurations
that can be achieved after each time step. For example, at 𝑡 = 3, the simplest tree is a single
evolving branch of length 4 that is obtained with a probability of q3. At the opposite end of the
spectrum, the most complex tree contains 8 active branches of length 1, obtained with
probability p7. The associated probabilities can be determined by computing the products of
individual probabilities along the arrows. Each tree has an associated probability and some of the
trees listed have multiple replicates (shaded boxes)
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3.1.2 Discrete probability distribution for the evolving family of trees
An example of a probability table thus generated is shown in Table 3 for the first three
time steps depicted in Figure 6. We assume that the parameter most reflective of the probability
of finding a target at a given distance from the starting point is the number of active branches at
that distance. This is due to the fact that since in the first order approximation we do not care
about the detailed neural structure at a distance from the origin, the probability of success in a
blind search is proportional to the number of local branches. The stepwise mean and variance
of the expected number of branches at this distance from the origin can then be determined as
a function of the branching probability p. We use the following formulas for expected mean and
variance: 𝑥 = ∑𝑛𝑖=1 𝑥𝑖 ∙ 𝑝𝑖 and 𝑉𝑎𝑟𝑖𝑎𝑛𝑐𝑒 = 𝜎 2 = ∑𝑛𝑖=1(𝑥𝑖 − 𝑥)2 ∙ 𝑝𝑖 for the discrete probability
distributions listed in Table 3 for the first few time steps.
Table 3 Average number of active branches and the associated variances for the first two time
steps.
Tree

Probability

# active

Total

Expected

branches

length

value

Step 0
1

1

1

2

1

0

(1+p)

- p2 + p

(1 + p)2

- p4 - 2p3 + p2 +

1

Step 1
1

Variance σ2

q

1

2

p

2

3

Step 2

2p
1

qq

1

3

2

qp

2

4

39

pq2

2

5

p (2pq)

3

6

4

7

3

4

Two possible trees
pp2 = p3

5

These results suggest a clear formula for the expected mean:
𝐸(𝑛) = (1 + 𝑝)𝑛
This result is intuitive; for example, if there are 100 active branches and a 10% probability of
branching, at the next time step we expect 110 active branches, followed by 121 at the next time
step and so on. We prove this formula analytically using the complete discrete probability
distribution of possible neuronal trees in the Methods Section, where we also provide recurrence
formulas and analytical solutions for the variances. The expected number of active branches, as
well as the associated variances, for the first three time steps, are listed in Table 4.
Table 4 Expected mean and variance for the active (terminal) branches after N timesteps
N

Expected mean

Expected variance

1

1 + 𝑝

− 𝑝2 + 𝑝

2

(1 + 𝑝)2

− 𝑝4 − 2𝑝3 + 𝑝2 + 2𝑝

3

(1 + 𝑝)3
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− 𝑝6 − 4𝑝5 − 5𝑝4 + 𝑝3
+ 6𝑝2 + 3𝑝

3.2

Model with conditional constraint
3.2.1 Neuronal growth model with a length constraint

Similar to our previous results, we assume that the family of neuronal trees is subject to a
maximal length constraint since otherwise, the only optimal strategy would be to branch as
much as possible, which is in contrast with experimental results. Obviously when the total
length of the trees cannot exceed a set maximum value, some of the trees generated using
formula cannot be instantiated. This is illustrated in Figure 7 for trees with a maximum length of
7.

Figure 7 All possible trees of lengths below a maximum value of 7.
Trees that can no longer generate offspring have terminal branches shown in red. For example,
the 3-terminal branch tree listed at stage 3 already has a total length of 6. Therefore, even if all
its terminal branches merely extend, the resulting tree will have a length of 9, exceeding the
maximal possible value of 7. All other trees will have even larger total lengths.
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As a result, the expected geometrical growth is possible only near the origin, as the densest
possible trees start exceeding length constraints at larger distances. In fact, growth slows down
further away from the origin, reaches a peak value, and achieves a longer tail of decaying values
corresponding to neural trees that seldom branch. This is shown in Figure 8, again for the family
of trees that cannot exceed a total length of 7.

Figure 8 The expected number of branches as a function of distance for families of trees with
maximum length 7 and branching probability p = 0.5.
Close to the origin, the expected value of searching sites increases as a geometrical series (see
performances at step 2). However, this picture changes at large distances from the origin. There
is an optimal targeting region, indicated by the peak at step 3, and a long tail of decaying values
for steps 4 to 7. There are no possible trees for steps 8 or larger since a tree of the maximal size
of 7 cannot reach beyond a total distance of 7. Only one tree, the one that does not branch at
all and has a probability q6, will reach a distance d = 7 and will have only one active branch. Error
bars indicated the standard error at each iteration point and are computed for a sample size of
39 (this is the sample size of one of the experimental data sets we later used for comparison).
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As illustrated in Figure 9, we can use the probability distribution for all possible instantiation of
neuronal trees to determine the expected search performances of trees of maximum length L.
The coverage area extends from x = 1 to L. The initial rise in performance follows a geometrical
series trend that is determined by the exact value of the branching parameter p. The
performance at large distances away from the origin has a long tail, corresponding to the
increasingly smaller number of trees that can make it further and further. In terms of the exact
values of branching probability, trees that branch often will tend to cover the nearby area well
and will have very small chances of extending far away. In contrast, trees that seldom branch
will have a much-improved chance to explore farther in space, albeit while sending out fewer
branches. It is then intuitive that the optimal targeting region is determined by the exact value
of the branching probability parameter p, as illustrated in Figure 9. Here the average number of
dendrites at different time steps is shown for different values of branching probability p. This is
essentially the equivalent of a Sholl plot for neuronal trees. [53,54].
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Figure 9 Sholl plots for different branching probabilities p.
Expected number of dendrites at each time step is plotted for a tree of maximum possible length
of 16, for the branching probabilities in the set {0, 0.2, 0.4, 0.6, 0.8, 1}. Since the tree starts with
one branch, it can only extend for a maximum of 15 extra number of steps. The tree with 𝑝 = 0,
shown in blue, simply extends until it runs out of resources and generates a flat line of 1 expected
branch at each time step. In contrast, the tree with 𝑝 = 1 doubles the number of branches at
each time step and runs out of resources at step 3, achieving a maximum at the time it stops. In
between these two extremes, families of trees shift their optimal targeting regions farther away
as the branching probability decreases, at the cost of reducing the overall amplitude of the
corresponding peak values (success rates).

3.2.2 Long-range expected performances are also characterized by geometrical
series
Surprisingly, the right tail of the probability distribution also follows a geometrical distribution
with a factor of (1 + 3𝑝), although higher order corrections are needed when p takes on larger
values. This trend can be determined by examining the trees that have the furthest reach, which
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is listed in Figure 10.

Figure 10 Illustration of trees generated at very long distances.
Figure 10: We use the longest possible tree to generate all the trees that can be instantiated at
the previous time steps. For the cases listed here, only trees with a small number of terminal
branches, 1 to 4, can be instantiated, as the trees are back-generated for 5 time steps.
Using Figure 10, it is easy to see the expected number of branches at large distances, computed
under the assumption that we ignore trees with more than 4 terminal branches, follows the
recursive structure listed in column 2 of table 5. This approximation becomes more and more
accurate as the branching probability p goes to 0. Consequently, the ratio of performances at
successive time steps (going backward) is approximately 1 + 3𝑝, as shown in column 3 of table
5.
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Table 5 Approximate geometrical series for the right tail of the probability distribution.
Step

Expected number

N

qN

N–

qN-1 + 2pqN-2

1 + 3p + 5p2 + 7p3 + 9p4 + 11p5 + 0(p6)

qN-2 + 2pqN-3 + 2pqN-2

1 + 3p - p2 + 3p3 - p4 + 3p5 + 0(p6)

qN-3 + 2pqN-4 + 2pqN-3 + 2pqN-2

1 + 3p - 7p2 + 29p3 - 99p4 + 357p5 + 0(p6)

1
N–
2
N–
3
N–

qN-4

4

𝑃(𝑘)

Ratio 𝑃(𝑘 + 1)

+

2pqN-5 +

2pqN-4 +

2pqN-3 +

1 + 3p - 13p2 + 85p3 + 507p4 + 3073p5 +

2pqN-2

0(p6)

N–

qN-5 + 2pqN-6 + 2pqN-5 + 2pqN-4 + 2pqN-3 +

1 + 3p - 19p2 + 171p3 - 1447p4 + 12341p5

5

2pqN-2

+ 0(p6)

Summarizing the results from table 5, for very small branching probability p, we obtain the
following approximation:
𝑃(𝑁−2𝑘−1)
𝑃(𝑁−2𝑘)

𝑃(𝑁−2𝑘−2)

= 1 + 3𝑝 + (5 – 6𝑘)𝑝2 , 𝑃(𝑁−2𝑘−1) = 1 + 3𝑝 + (5 – 6(𝑘 + 1))𝑝2

(1)

This approximation is correct when discounting trees with more than two terminal branches, as
these trees will introduce corrections of order 𝑝2 and larger. We note while high values of the
branching probability 𝑝 render this approximation more and more inaccurate, in fact, low values
of p are needed for the neural trees to be able to reach large distances; therefore, this is a useful
approximation.
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3.2.3 Approximating the location of optimal targeting performances
We can now use the formula for long-range expected performances to compute an
approximation for the location of optimal targeting region. The ratio of performances that is
initially larger than 1 keeps decreasing as one moves away from the longest possible tree of
length L toward and closer to the origin. Eventually, this ratio, again based on extensions of
formula (1), will become 1 before further decreasing at distances closer and closer to the origin.
The exact location where the ratio becomes 1 can be used to approximate where the spatial
location of the peak of the distribution occurs. This occurs at step N – k, when

𝑃(𝑁−𝑘−1)
𝑃(𝑁−𝑘)

, which

starts with an initial value of (1 + 3𝑝 + 5𝑝2 ), reaches a value of 1 after experiencing continuous
decreases in value. This is determined by the following equation:
1 + 3𝑝 + (5 – 6𝑘)𝑝2 = 1
which can be easily rewritten as 3 + (5 – 6𝑘). 𝑝 = 0, yielding the following value of the peak:
𝑘=

3 + 5𝑝
3
, 6𝑝𝑘 = 3 + 5𝑝, (6𝑘 − 5)𝑝 = 3, 𝑝 =
(6𝑘 − 5)
6𝑝

A recurrence formula that takes into account terms up to order 𝑝3 is provided in the Methods
Section. When allowing for correction terms of orders up to p3, only numerical solutions for this
equation can be obtained since the coefficients have relatively complex recurrence formulas.
We now list another way of approximating the optimal targeting region. In previous study
[2], we derived an estimate of the location of optimal targeting performances by examining a
tree with neurites that branches periodically until growing a fixed length 𝐿0 , which is determined
by the branching probability 𝑝. After computing how L0 depends on 𝑝, we now can determine
the optimal targeting region after 𝑛 steps:
𝑛=

ln(1 + 𝑝𝐿)
−1
ln(1 + 𝑝)

Derivation of this equation is listed in the Methods Section. This equation determines the optimal
targeting region for a tree with branching probability 𝑝. Note that here 𝑛 is a continuous function
of 𝑝 since the branching probability can take continuous values. This ‘naïve’ approximation is in
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very good agreement with the results from the discrete probability distribution obtained by
instantiating all possible trees that do not exceed the maximal value 𝐿 up to time step 𝑛, as
shown in Figure 11.

Figure 11 Comparison of naïve vs exact results for a tree of maximum length L = 31.
We use the explicit discrete probability distribution to determine the optimal targeting regions,
shown as blue circles, while the red line is given by equation𝑛 =

ln(1+𝑝𝐿)
ln(1+𝑝)

− 1. For the discrete

distribution, since the total length of the tree is 31, there are enough resources for all possible
trees until step 4. Therefore, the optimal branching probability is𝑝 = 1, corresponding to
creation of the densest trees. As a result, steps 1-4 are excluded from the comparison. The blue
points are computed using the explicit symbolic equation (polynomials in𝑝) for the expected
value 𝑠𝑘 at different locations𝑘 < 𝑛. Then the solution for the probability 𝑝 that maximizes the
expected value 𝑠𝑘 (𝑝) is computed and plotted at location k as a blue circle. Values for p are
restricted to be between 0 and 1 to exclude other potential solutions for the polynomial
equations. The graph indicates that while the red curve obtained from the ‘naïve’ theoretical
expectation overestimates the analytical expected results, these curves are in agreement and
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exhibit the same trends. Furthermore, as expected, the approximation used in equation 𝑝 =
3
, shown here in green, works relatively well at large distance, but it loses accuracy at
(6𝑘−5)
distances close to the origin. Nevertheless, higher order terms need to be used in order to obtain
a more useful approximation.

3.3

Comparison with lab data
3.3.1 Comparison of the theoretical and experimental results for neural growth

In order to assess the validity of our model, we performed a comparison with experimental data
from neuronal growth tissue from the Firestein laboratory. An illustration of two sample neurons
is provided in Figure 12. We performed Sholl analysis for the family of neurons used here in order
to generate the targeting profiles. We fit our models to these profiles by allowing changes in the
following parameters: spatial distance covered in between two potential branching events (width
of the distribution), the number of initial branches (peak of the distribution) and branching
probability/total length. We were able to produce very accurate fits for the Sholl analysis curves
(Fig 12), indicating that our model is in very good agreement with the experimental data.
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Figure 12 Comparison of experimental and theoretical results.
Arborization profiles for two example neurons (A and B) result in typical profile curves (blue
curve in panel C) for this family of neurons (n = 30). Fits of the probabilistic neuronal growth
model are in excellent agreement (red curve in panel C).

Our model suggests that the logarithm of the number of active branches is a more appropriate
way of constructing Sholl plots, as the average function of the neuronal tree population is
predicted to have a linear component near the origin and approximate linear component at
large distances. The use of both of these components can provide a better statistical
determination of branching values. Also, if the large-distance component is in disagreement
50

with the near-origin component, this may indicate other effects, such as pruning at larger
distances or parameter-dependent branching.
With our model, we are able to connect branching parameters with real branching probabilities
and also reflect the effect of chemicals on branching probability, such as Cypin , GFP and NOS..


Cypin: a guanine deaminase that increases dendrite number by binding to tubulin
heterodimers and promoting microtubule assembly [55]. In our study, it is taken as a
chemical that increases the branching probability.



Green fluorescent protein (GFP): a protein composed of 238 amino acid residuals that
exhibit bright green fluorescence when exposed to light in the blue to ultraviolet range.
Iin our study, it is used as a control group [56].



Nitric Oxide synthase: a family of enzymes catalyzing the production of nitric oxide from
L-arginine [57]. In our study, it is taken as a chemical that decreases the branching
probability.

In order to accomplish this task, we first tried to build up our model with data from our
collaborator to estimate the branching probability. We set the total length to be 34, due to the
limitation of our capacity in generating all possible trees Results show below:
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Figure 13 Results from estimating the branching probability
Figure13: The figure shows the comparison between the expected value from our model (in
blue) and the real data (in red). The estimate of branching probability was obtained when we
have the least difference between the model and real data. Meanwhile, horizontal shift was
applied to the model, in order to have the proper initial number of branches. We can see that
their confidence intervals overlap, which means that our model fits well with the real data.
We also have the ANOVA result:
Table 6 ANOVA results from estimating branching probability
Nonlinear Regression Model:
𝑦 ~ 𝑓𝑖𝑡 (𝑏𝑟𝑎𝑛𝑐ℎ𝑖𝑛𝑔 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦, 𝑆𝑡𝑒𝑝)

Estimated Coefficients:
Estimate

SE

tStat
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P-value

Branching probability

0.1465

0.0059766

24.512

2.127e-21

Number of observations: 31, Error degrees of freedom: 30
Root Mean Squared Error: 0.186
R-Squared: 0.965, Adjusted R-Squared: 0.965
F-statistic vs. zero model: 1.83e+03, P-value: 1.9e-28

From the results, we can see that our model fits well and R-square looks promising for applying
the model for new data. Then we tried to compare the branching probability between neural
growth processes controlled by different chemicals, which influence the branching probability.
We first compared NOS vs GFP, expecting a reduction of branching probability between NOS
condition and control (GFP), [55-57]:
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Figure 14 Comparison between NOS vs GFP
Figure 14: comparison between two regeneration controlled by NOS (left) and GFP(right). With
our model, we estimate the branching probability to obtain the best fit. We also move our
model horizontally with different units, according to the different initial number of branches.
We also have the comparison between the estimate two branching probabilities listed below
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Table 7 Comparison between branching probabilities of two processes
NOS
Estimate

GFP

95% Confidence Interval

95% Confidence Interval

Branching
0.1

0.0962

0.1038

0.1465

0.1405

0.1525

probability

Then, we compared Cypin vs GFP:
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Figure 15 Comparison between GFP and Cypin
Figure 15: comparison between two regeneration controlled by GFP (left) and Cypin(right).
Same as first pair, we obtain the estimate the branching probability based on the goodness of
fit. Horizontal shift was also applied here to have the proper initial number of branches. We
also have the comparison between two estimate of branching probabilities listed below

Table 8 Comparison between branching probabilities of two processes
GFP
Estimate

Cypin

95% Confidence Interval
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95% Confidence Interval

Branching
0.0788

0.0708

0.0868

0.1284

0.1216

0.1352

probability

So from the results above, we can see that the differences between branching probabilities are
significant, none of the confidence intervals overlap. This tells us that our model is capable
reflecting the effect from these medicals on the branching probability. For example, Cypin was
expressed early in culture and continued to be expressed as neurons matured [58 in invivo]. So
it is expressed in developing dendrites and increases the branching probability, which is in
accordance with our results in table 8. The branching probability of process with Cypin is
significantly higher than the other.
In the future, we aim to test our model on processes controlled by same chemical substances,
but with different concentrations, as experimental data becomes available.

3.4

Results for Tumor growth rate
3.4.1 Tumor volume and growth rate:

Tumor volume at the time of screening ranged from 33-25918mm3 (mean=1382.7mm3 and
median 472.29mm3). This contrasted with tumor volume at diagnosis, which was found to range
from 9 to 37819mm3 (mean=4591.74mm3 and median =2365.80mm3).
Overall, change in volume between screening and diagnosis in each patient varied significantly.
Six cases showed no change in size, while the largest change in tumor volume was 18438.1mm3.
The mean time difference between dates of screening and that of diagnosis was 18 months,
(median = 17.5 months), and ranged from 4 to 47 months.
The growth rate was found to differ considerably from patient to patient, ranging from 0 to 1390
mm3/month. (Figure 18) Tumors with a growth rate of <92mm3 per month were deemed slowgrowing and comprised 47 cases (49.5%). In contrast, those with a growth rate of ≥92mm3 per
month (n = 48, 50.5%) were placed in the fast-growing group.
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Figure 16 Histogram of tumor volume at diagnosis and screening and also histogram of the
change in tumor size
Age at the time of diagnosis ranged from 50 to 73 years of age (mean = 60.3 years, median = 61.0
years). Most cases (n=60) were negative for vascular invasion (66.2%), whilst 21 (22.8%) were
found to demonstrate definite vascular invasion, and 11 (11.0%) were rated as probable. The
majority of tumors (60, 65.2%) were stage 1, 24 were stage 2 (26.1%), and 7 cases were stage 3
(8.7%). 16 tumors were graded as 1 (17.4%), using the Nottingham Grading System, 42 cases
(45.7%) were grade 2, and 34 (36.9%) grade 3. DCIS was not observed in 21 cases (22.8%). Of the
remaining 73 cases, 20-showed low-grade DCIS (21.7%), 16 were of intermediate grade (17.4%),
5 were intermediate/high grade (5.9%), and the remaining 29 high grade (31.5%). The mean NPI
value was 4.00, with a range of 2.08 to 6.56 (median = 4.01). The clinicopathologic features of
patients are summarized in the following table 9.
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Table 9 Clinicopathological features of cases
Parameters
Age
≤65
>65
Tumor Grade
1
2
3
Clinical stage
I
II
III
HORMONE STATUS
ER Positive
PR Positive
HER2 Expression
Positive
Negative
Tumor type
NST
LOB
TUB
MUC
MIX
Vasicular Invasion
NEG
DEFINITE
PROBABLE
KI67
High
Low
CK5/6
Negative
Positive
Caspase3
0
≥1
Subtypes
Luminal
Her2
Basal
TN

Number of cases (N)

Percentage (%)

74
18

77.9
22.1

16
42
34

17.4
45.7
36.9

60
24
7

65.2
26.1
8.7

78
59

84.8
64.1

5
81

5.85
94.2

50
17
11
2
12

54.3
18.5
12.0
2.2
13

60
21
11

66.2
22.8
11.0

44
48

47.8
52.2

80
12

87
13

45
47

49
51

69
8
4
11

75
8.7
4.3
12
57

Vital Status
Alive
Dead

62
30

67.4
32.6

Tumor Biomarker Profiles
Of the 92 cases, 78 cases were positive for ER (84.8%) and 59 cases were positive for PR (64.1%)
while only 5 cases were positive for HER-2 based on protein expression (5.8%). The degree of
Ki67 staining ranged from 0 to 96% of tumor cells stained. In the case of CK5/6, 80 cases (87%)
were negative, and just 12 (13%) showing positive staining. Cleaved caspase-3 immunoreactivity
ranged from 0 to 6.0% of tumor cells (Table: 10).
3.4.2 Results from neural growth model selection
Here we have the results from three models.
The first model is linear model, with formula:
𝑉𝑡 = 𝛼 ∗ ∆𝑡 + 𝑉0
Then, we fit the linear model based on the formula and estimate the growth rate.
The results from linear model:
Table 10 ANOVA results from linear model
Analysis of Variance
Source

DF

Model

1

Sum of
Squares

Mean F Value Pr > F
Square

58924223 58924223

2.57 0.1123

90 2062334567 22914829

Error

Corrected Total 91 2121258789
Root MSE

4786.94355 R-Square 0.0278

Dependent Mean 3208.99969 Adj R-Sq 0.0170
Coeff Var

149.17245
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Parameter Estimates
Variable

DF Parameter
Estimate

Standard t Value Pr > |t|
Error

Intercept

1 1649.30376 1093.20595

input_linear

1

86.64977

54.03545

1.51 0.1349
1.60 0.1123

Figure 17 Fit plot of linear neural growth rate model
From the results, we can see that the p-value of F-test is greater than 0.05, which means that the
model is not good at overall fitting. The r-squared is 0.02, which means that the model only
explains 2% of the variation of output. This indicates that the linear model might not be a good
choice for the neural growth rate.
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We also have the model diagnostic results as shown in figure 18.

Figure 18 Diagnostic results of linear neural growth model
Figure 18 is the results from model diagnosis. From the top residual plots, we can see that the
residuals are not normally distributed and also have clear pattern as the predicted value increases,
which mean the model can be improved. Also from the qq-plot and residual histogram, we can
see that the model violates several modelling assumptions. Therefore, the linear model is not a
good choice to predict the growth rate.

The second model we tried is exponential model with the formula:
𝑉𝑡 = 𝑉0 ∗ 𝑒 𝛼∗∆𝑡
Before we fit the model to estimate the growth rate, we did the transformation to have the
linear form as:
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𝑉𝑡
ln ( ) = 𝛼 ∗ ∆𝑡
𝑉0
Then we have the results from exponential model:
Table 11 ANOVA results from exponential neural growth model
Analysis of Variance
Source

DF

Model

1

Error

90

Sum of
Squares

Mean F Value Pr > F
Square

15.08707 15.08707
85.55486

15.87 0.0001

0.95061

Corrected Total 91 100.64193
Root MSE

0.97499 R-Square 0.1499

Dependent Mean

1.47208 Adj R-Sq 0.1405

Coeff Var

66.23239
Parameter Estimates

Variable

DF Parameter Standard t Value Pr > |t|
Estimate
Error

Intercept

1

0.68286

0.22266

3.07 0.0029

input_exp

1

0.04385

0.01101

3.98 0.0001
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Figure 19 Fit plot for exponential neural growth rate model
From the results, we can see that the p-value of F-test is less than 0.0001, which means that the
model is good at overall fitting. The r-squared is 0.1499, which means that the model only
explains 14% of the variation of output.
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We also have the model diagnostic results as shown in figure 20.

Figure 20 Diagnostic results of exponential neural growth model
Figure 20 is the results from model diagnosis. From the top residual plots, we can see that there
are not clear patterns in the residual plots, which mean the model has good robustness. Also
from the qq-plot and residual histogram, we can see that the model meet most of modelling
assumptions. Therefore, the exponential model is a good choice to predict the growth rate.

The last model we tried is Gompertz model:

𝑉𝑡 = 𝑉0 ∗
We also transformed it into linear form as:
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𝛼
∆𝑇
𝑒 1− 𝑘

𝑉𝑡
𝛼
ln ( ) =
∆𝑇
𝑉0
1−
𝑘
The result from fitting Gompertz model:
Table 12 ANOVA results from Gompertz neural growth model
Analysis of Variance
Source

DF

Model

1

Error

90

Sum of
Squares

Mean F Value Pr > F
Square

12.51102 12.51102
88.13091

12.78 0.0006

0.97923

Corrected Total 91 100.64193
Root MSE

0.98956 R-Square 0.1243

Dependent Mean

1.47208 Adj R-Sq 0.1146
67.22212

Coeff Var

Parameter Estimates
Variable

DF Parameter Standard t Value Pr > |t|
Estimate
Error

Intercept

1

1.90810

0.15976

11.94 <.0001

input_third

1

0.39765

0.11125

3.57 0.0006
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Figure 21 Fit plot of Gompertz neural growth model
From the results, we can see that the p-value of F-test is 0.0006, which means that the model is
good at fitting. The r-squared is 0.1243, which means that the model only explains 12% of the
variation of output.

65

We also have the model diagnostic results as shown in figure 22.

Figure 22 Diagnostic results of Gompertz neural growth model
Figure 22 is the results from model diagnosis. From the top residual plots, we can see that there
are clear expanding patterns in the residual pattern as the prediction increases, which mean the
model is good in predicting. But from the qq-plot and residual histogram, we can see that the
model meets the modelling assumptions. In sum, the Gompertz model is the best choice to
predict the growth rate.
Based on the results above, we have the conclusion that exponential model is the best one among
the three candidates.

3.4.3 Correlation study on growth rate and biomarkers
We also tested the correlation between the growth rate and biomarkers, trying to define the
effect of the biomarkers on determining the growth rate. By doing this, we will test the
hypothesis that patients at higher cancer stage tend to have faster tumor growth rate. What is
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more, this study will help us to choose the biomarkers to build the model predicting the tumor
growth rate.
Correlations between Other Clinicopathological Parameters and Growth Rate:
The Growth rate in breast cancer was significantly and positively correlated with tumor grade (p
= 0.0247), histological size (p=0.001) and vascular invasion (p = 0.011). When sub-dividing tumor
grade into its 3 components, the degree of tumor differentiation was found to have no significant
relationship with growth rate (p = 0.486), however, mitotic index was significantly correlated (p
= 0.0032). Stage showed no significant relationship with growth rate (Table: 13).
Correlations between Biomarker Expression, clinicopathological parameters, and Growth Rate :
A highly significant correlation was found between the proliferative marker Ki67 and tumor
growth rate. (Pearson correlation coefficient=0.36457; p=0.0004). Higher growth rate was also
positively correlated with increasing Mitosis (Pearson correlation coefficient=0.31, p=0.0019),
higher Grade (Pearson correlation coefficient=0.23411, p=0.0247), NPI (Pearson correlation
coefficient=0.27698, p=0.0075) and Caspase3 (Pearson correlation coefficient=0.30380,
p=0.0373) as shown in figure 23.

(a)

(b)

67

(c)

(d)

(e)
Figure 23 Significant correlation between tumor growth rate with (A) Ki67; (B) Caspase3; (C)
Grade; (D) NPI and (E) Mitosis

Correlation among tumor biomarkers: A highly significant relationship was observed between
cleaved Caspase-3 and Ki67 expression, with the two being positively correlated (p = 0.001,
Pearson’s correlation coefficient = 0.259, Figure 24).
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Figure 24 Relationship between Ki67 and Caspase-3 expression
We also have

Table 13 Relationship between growth rate and biomarkers
Variables

Growth rate
Low (<92 mm3/month)

High (≥92mm3/month
P-

#

%

#

%

X2
VALUE

Grade
1

4

8.16

12

27.91

2

20

40.82

22

51.16

3

25

51.02

9

20.93

Total

49

43

69

11.2813

0.0036

T
1

2

4.08

2

4.65

2

14

28.57

19

44.19

3

33

67.35

22

51.16

Total

49

2.5772

0.2757

5.7439

0.0566

11.5204

0.0032

43

P
1

0

0.00

3

6.98

2

18

36.73

21

48.84

3

31

63.27

19

44.19

Total

49

43

M
1

18

36.73

30

69.77

2

10

20.41

7

16.28

3

21

42.86

6

13.95

Total

49

43

TYPE
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LOB

11

22.45

6

13.95

MED

0

0.00

0

0.00

MIX

5

10.20

7

16.28

MUC

0

0.00

2

4.65

NST

29

59.18

21

48.84

TUB

4

8.16

7

16.28

Total

49

5.5343

0.2367

4.6488

0.0978

13.599

0.0011

43

STAGE
1

28

57.14

33

76.74

2

17

35.42

7

16.28

3

4

8.33

3

6.98

Total

49

43

Vi
Negative

24

48.98

36

83.72

Probable

7

14.29

4

9.30

Definite

18

36.73

3

6.98

Total

49

43
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Histological
size
≤15mm

8

>15mm

41

Total

49

16.32
83.68

24
19

55.81
14.7778

0.0001

16.3576

0.0003

44.19

43

NPI
GPG

10

20.40

26

60.46

MPG

31

63.26

15

34.88

PPG

8

16.32

2

4.65

Total

49

43

Table13: Grade = overall tumor grade, (based on Nottingham grading System), Type = histological
tumor type (Lobular, Atypical Medullary, Mixed, Mucinous, Non-specific Type, Tubular), Stage =
tumor stage, Vi = degree of vascular invasion, Hist. Size = histological tumor size (15mm being
the standard clinical cut-off for dichotomization), NPI = Nottingham prognostic index (using
standard clinical cut-offs). Components of the Nottingham grading system; T= degree of tumor
differentiation, P = nuclear pleomorphism, M = mitotic index. NPI calculated as (0.2 x Hist Size in
cm) / (stage + grade), GPG = Good prognostic group (NPI<3.41), MPG = Moderate prognostic
group (NPI >=3.41 and <=5.40), PPG = Poor prognostic group (NPI >5.4)

Furthermore, we also tested the correlation between the growth rate and the difference
between Ki67 and cleaved Caspase-3. We observed a significant correlation (p = 0.0017)
indicating that the tumor growth rate is correlated with the balance between ki67 and caspase3.
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Table 14 Relation between Ki67 and Caspase3 expression
Change in growth rate

Pearson correlation

P-value

Difference in Ki67 and
Coefficient
cleaved Caspase3
0. 41766

<0.001

Correlation between breast cancer subtype and growth rate:
A highly significant positive correlation (p<0.05) was observed between subtypes of breast cancer
and tumor growth rate. The tumor growth rate varied significantly between the breast cancer
subtypes (Figure: 25). Furthermore, when growth rate between TNBC and non-TNBC subtypes
were compared we observed a higher tumor growth rate among TNBC cohort compared to other.

(a)

(b)

Figure 25 Comparison of growth rate among different type of Breast Cancer
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3.4.4 Results from survival analysis on the tumor growth data
The increase in tumor growth rate significantly increases the risk to death: When tumor growth
rate was considered as the predictive marker for survival, a univariate analysis revealed that the
risk to death increases as the growth rate increases. With every unit of positive change in tumor
growth change, the risk to death also increases (HR=1.073, P=0.0268) Table: 15. Furthermore,
when Age, Grade, and ki67 were adjusted in the multivariate approach, tumor growth rate is still
a significant predictor of overall survival (HR= 1.071 and p= 0.0435)
Table 15 Survival analysis for monthly growth rate
Variable

Univariate Analysis

Hazard Ratio

Growth rate

95% Confidence interval

P-value

1.008-1.143

0.0268

1.073

Table 16 Survival analysis with adjusting age, Ki67, and grade
Multivariate analysis
Variable

95% Confidence
Hazard Ratio

P-value
interval

Growth rate

1.071

1.002-1.145

0.0435

Age

0.995

0.976-1.014

0.6111

Grade

1.033

0.545-1.96

0.9204

Ki67

1.002

0.977-1.027

0.8894
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3.4.5 Results from optimize the cutpoint
After finding the best cutpoint 0.1, we plot the survival curves for both fast growth group and
slow growth group. The difference between them is significant. We have the p-value for ChiSquare Log-Rank test as 0.0245, which means that the patients with fast growth rate have a
higher risk to death.

Figure 26 Survival Curve for different groups
Figure 26 shows the results for the survival curves of two groups when we choose 0.1 as the
cutpoint to separate fast growth group from slow growth group. The p-value for the Chi-Square
test Log-Rank test is 0.0245

3.4.6 Results from logistic regression modeling on the growth rate
After applying the method described in the section 2.4.6, we obtained the best model as
following:
ln (

𝑝
) = 𝛽0 + 𝛽1 ∗ 𝐶𝑎𝑠𝑝𝑠3𝑆𝑐𝑜𝑟𝑒 + 𝛽2 ∗ 𝐺𝑟𝑎𝑑𝑒 + 𝛽3 ∗ 𝐻𝐸𝑅 + 𝛽4 ∗ 𝐾𝑖67𝑆𝑐𝑜𝑟𝑒 + 𝛽5 ∗ 𝑀
1−𝑝
+ 𝛽6 ∗ 𝐴𝑔𝑒 + 𝛽7 ∗ 𝐴𝑔𝑒 ∗ 𝑇 + 𝛽8 ∗ 𝐶𝑎𝑠𝑝𝑠3𝑆𝑐𝑜𝑟𝑒 ∗ 𝐴𝑔𝑒
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Model Fit Statistics
Criterion Intercept Only Intercept and
Covariates
AIC

117.059

115.036

SC

119.547

142.411

-2 Log L

115.059

93.036

Testing Global Null Hypothesis: BETA=0
Test

Chi-Square DF Pr > ChiSq

Likelihood Ratio

22.0231 10

0.0150

Score

20.2071 10

0.0274

Wald

14.7686 10

0.1407

Type 3 Analysis of Effects
Effect

DF

Wald Pr > ChiSq
Chi-Square

CASP3_SCORE

1

1.3969

0.2372

Grade

2

4.3468

0.1138

HER11

1

1.1243

0.2890

KI67_SCORE

1

3.9386

0.0472

M

2

3.5307

0.1711

AGE

1

2.9366

0.0866

AGE*T

1

2.8339

0.0923

CASP3_SCORE*AGE

1

1.4302

0.2317

Analysis of Maximum Likelihood Estimates
Parameter

DF Estimate Standard
Wald Pr > ChiSq
Error Chi-Square

Intercept

1

-0.7431

2.3468

0.1003

0.7515

CASP3_SCORE

1

3.4762

2.9412

1.3969

0.2372

Grade

1

1

-1.4743

0.7986

3.4085

0.0649

Grade

2

1

0.5804

0.5030

1.3317

0.2485

HER11

0

1

-0.7044

0.6643

1.1243

0.2890

1

-0.0365

0.0184

3.9386

0.0472

KI67_SCORE
M

1

1

1.2064

0.8127

2.2032

0.1377

M

2

1

-0.6599

0.4431

2.2178

0.1364

AGE

1

0.0830

0.0484

2.9366

0.0866

AGE*T

1

-0.0183

0.0109

2.8339

0.0923
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Analysis of Maximum Likelihood Estimates
Parameter
CASP3_SCORE*AGE

3.5

DF Estimate Standard
Wald Pr > ChiSq
Error Chi-Square
1

-0.0577

0.0483

1.4302

0.2317

Results from extending the survival analysis on the breast cancer recurrence
3.5.1 Clinico-pathological characteristics of patients

The demographics, breast clinico-pathological characteristics, therapies administered and
patterns of recurrence among the patients in the cohort are illustrated in the figure 27. From this
cohort of 10,504 NH patients, 225 were recorded as having experienced a recurrence episode
and 6,009 were determined as displaying no breast tumor recurrence. The remaining patients
did not have recorded data indicating the presence of recurrence or lack thereof. Among patients
displaying recurrence, higher risk of recurrence was more prevalent among younger patients
(p<0.0001).
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Figure 27 NH demographics and breast cancer clinico-pathological characteristics compared
between patients with or without tumor recurrence
This result is consistent with previous studies that have observed an association between
78

younger age and increased risk for recurrence [58, 59]. Among patients with no missing
recurrence data, approximately 61% of patients who experienced recurrence were under the age
of 48, compared to only 39% who did not experience any recurrence. Among breast clinicopathological characteristics, recurrence was significantly more associated with higher nuclear
grade, NGH grade, stage, as well as T, N, and M classifications (p<0.0001). Moreover, recurrence
was weakly associated with lymph node metastasis with roughly 35% of patients with recurrence
displaying a positive nodal status compared to only 15% of non-recurrence patients (p=0.121).
These results further confirm previous findings of increased risk of recurrence associated with
more aggressive tumor characteristics (48). Regarding treatment, there were significant
differences in the distribution of recurrence and non-recurrence patients who were administered
neoadjuvant and adjuvant chemotherapy, hormone therapy, and a combination of adjuvant
therapies (p<0.0001). There was a weak statistical significant difference between the proportion
of recurrence and non-recurrence patients that received radiation therapy (p=0.065). Please visit
Table 17 for details.
Table 17 NH demographics and breast cancer clinico-pathological compared between patients
with or without tumor recurrence
Recurrence

No recurrence

Clinical
n=225

%

n=6009

%

49

21.78

1047

17.42

166

73.78

4607

76.67

10

4.44

355

5.91

P

characteristic
Ethnicity
AA

EA
Unknown/Other
Menopausal status

79

0.2014

<48

89

39.56

1496.00

24.90

48-55

41

18.22

1236.00

20.57

>55

95

42.22

3277

54.53

1

23

10.22

1641.00

27.31

2

82

36.44

2472.00

41.14

3

105

46.67

1484.00

24.70

Missing

15

6.67

412.00

6.86

1

13

5.78

1128.00

18.77

2

31

13.78

1448.00

24.10

3

35

15.56

890.00

14.81

Missing

146

64.89

2543.00

42.32

0

24

10.67

1518.00

25.26

I

76

33.78

2793.00

46.48

IIa,b

77

34.22

1360.00

22.63

IIIa,b,c,NOS

32

14.22

271.00

4.51

IV

10

4.44

26.00

0.43

<0.0001

Nuclear grade
<0.0001

Nottingham grade
<0.0001

Stage

80

<0.0001

Missing/unknown

6

2.67

41.00

0.68

Positive

78

34.67

911.00

15.16

Negative

106

47.11

3920.00

65.24

Missing/unknown

41

18.22

1170.00

19.47

T0

2

0.89

6.00

0.10

TX

2

0.89

30.00

0.50

Tis

24

10.67

1518.00

25.26

T1

100

44.44

3245.00

54.00

T2

67

29.78

1034.00

17.21

T3

14

6.22

123.00

2.05

T4

13

5.78

43.00

0.72

Unknown

3

1.33

10.00

0.17

N0

141

62.67

5011.00

83.39

NX

1

0.44

9.00

0.15

N1

56

24.89

783.00

13.03

Nodal status
0.121

TNM Staging
T
<0.0001

N

81

<0.0001

N2

17

7.56

150.00

2.50

N3

7

3.11

46.00

0.77

Unknown

3

1.33

10.00

0.17

M0

211

93.78

5962.00

99.22

MX

1

0.44

11.00

0.18

M1

10

4.44

26.00

0.43

Unknown

3

1.33

10.00

0.17

Yes

158

70.22

3793

63.12

No

67

29.78

2216

36.88

Unknown

0

0.00

0

0.00

Neoadjuvant

40

17.78

625

10.40

Adjuvant

78

34.67

1272

21.17

None

92

40.89

3952

65.77

Missing

15

6.67

160

2.66

M
<0.0001

Lymph node
surgery
0.0169

Chemotherapy

Hormone therapy

82

<0.0001

Yes

90

40.00

3123

51.97

No

119

52.89

2705

45.02

Unknown

16

7.11

181

3.01

Yes

109

48.44

2963

49.31

No

96

42.67

2732

45.47

Unknown

20

8.89

314

5.23

Yes

78

35.94

1272

21.42

No

132

60.83

4577

77.07

Unknown

15

6.91

160

2.69

<0.0001

Radiation therapy
0.0649

Adjuvant therapy
<0.0001

3.5.2 Recurrence pattern among racially distinct patients
Recurrence rates and patterns, expressed in terms of incidence rates, were compared broadly
between AA and EA patients (Table 18); the analysis indicated that AA exhibited higher overall
tumor recurrence rates than EA (p=0.002; HR: 1.676; CI: 1.210-2.323). AA also displayed higher
rates of distant recurrence than EA (p=0.023; HR: 1.699; CI: 1.075-2.684); however, these
differences did not remain statistically significant after controlling for age, grade, and stage, likely
owing to low patient numbers. Additionally, AA experienced higher rates of single tumor
recurrence episodes than EA (p=0.003; HR: 1.758; CI: 1.208-2.557) and higher rates of distant
recurrence to a single site than EA breast cancer patients (p=0.012; HR: 1.742; CI: 1.130-2.684),
although statistical significance was not maintained after adjusting for age, grade, and stage
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Table 18 Broad spectrum recurrence patterns among racially distinct populations
EA

Overall

AA

n

IR

n

IR

166

13.44

49

21.77

p value; HR (95% CI)

p value; HR (95% CI)

Unadjusted Model

Adjusted Model

0.002; 1.676 (1.210,

0.319; 1.192 (0.844,

2.323)

1.683)

0.373; 1.349 (0.698,

0.665; 0.857 (0.428,

2.606)

1.718)

0.188; 1.701 (0.772,

0.151; 1.749 (0.815,

3.747)

3.752)

0.023; 1.699 (1.075,

0.280; 1.299 (0.809,

2.684)

2.085)

0.003; 1.758 (1.208,

0.218; 1.287 (0.861,

2.557)

1.923)

0.754; 1.139 (0.505,

0.315; 0.652 (0.283,

2.573)

1.503)

0.012; 1.742 (1.130,

0.451; 1.220 (0.728,

2.684)

2.043)

0.492; 1.566 (0.436,

0.617; 0.672 (0.142,

5.625)

3.187)

Recurrence site

Local

Regional

Distant

48

27

84

3.89

2.19

6.8

12

10

27

5.33

4.44

12

Number of recurrences

Single

Multiple

131

35

10.6

2.83

41

8

18.21

3.55

Distant recurrence

Single site

Multiple sites

73

11

5.91

0.89

24

3

10.66

1.33

84

Abbreviations: AA, African-American; EA, European-American; HR, hazard rate; IR, incidence rate
(1000 person-years); CI, confidence interval.
Adjusted Cox hazard model variables: age at diagnosis, grade (1,2,3), and stage (I,II,III,IV).
*P values were calculated using the student t-test.

3.5.3 Recurrence patterns among racially distinct patients following each form of
treatment
Incidence rates and patterns of recurrence were compared between AA and EA after they
received hormone, radiation, chemotherapy, and/or any combination of adjuvant therapy to
determine distinctions in recurrence patterns between therapies among the racial groups (Table
19). AA exhibited unadjusted higher rates of recurrence (p=0.041; HR: 1.612; CI: 1.021-2.545) and
a trend towards higher incidence of distant recurrence than EA post radiation therapy (p=0.065;
HR: 1.732; CI: 0.967-3.100). The same trend of higher overall and distant recurrence was
observed among recurrent patients who received hormone therapy and any combination of
adjuvant therapies. Among patients who underwent hormone therapy, AA displayed stronger
overall tendencies than EA to suffer from recurrence (p=0.112; HR: 1.541; CI: 0.906-2.623) and
distant recurrence (p=0.123; HR: 1.692; CI: 0.868-3.301). Following any combination of adjuvant
therapy, AA displayed higher recurrence rates than EA after adjusting for age, grade, and stage
(p=0.015; HR: 1.699; CI: 1.108-2.606). Moreover, unadjusted analyses reveal AA displayed higher
rates of distant recurrence than EA (p=0.003; HR: 2.164; 1.290-3.629) as well as stronger
tendencies toward regional recurrence (p=0.104; HR: 2.043; CI: 0.863-4.837) after receiving any
combination of adjuvant therapy.
Table 19 Recurrence rates and patterns after receiving any form of treatment among racially
distinct populations
EA

AA

p value; HR (95% CI)

85

p value; HR (95% CI)

Treatment

n

IR

n

IR

85

22.73

23

26.66

Unadjusted model

Adjusted model

0.466; 1.181 (0.755,

0.807; 0.943 (0.587,

1.846)

1.514)

0.125; 2.053 (0.818,

0.394; 1.548 (0.567,

5.151)

4.226)

0.594; 1.284 (0.512,

0.749; 1.169 (0.450,

3.219)

3.041)

0.832; 0.934 (0.498,

0.613; 0.840

1.751)

(0.426,1.653)

0.373; 0.673 (0.281,

0.409; 0.690 (0.286,

1.609)

1.664)

0.026; 6.857 (1.256,

0.024; 7.134 (1.295,

37.447)

39.313)

N/A

N/A

0.112; 0.310 (0.073,

0.136; 0.332 (0.078,

1.315)

1.417)

0.405; 1.253 (0.737,

0.891; 1.039 (0.603,

2.130)

1.788)

Chemotherapy

Overall

Local

Regional

Distant

13

20

50

3.48

5.35

13.37

7

6

12

7.46

6.4

12.79

Neoadjuvant chemotherapy

Overall

Local

32

2

28.95

1.81

6

4

19.77

13.18

Regional

7

6.33

0

0

Distant

23

20.81

2

6.59

Adjuvant chemotherapy

Overall

57

20.96

18

26.16

86

Local

Regional

Distant

12

15

30

4.41

5.52

11.03

3

6

9

0.865; 0.897 (0.255,

0.500; 0.645 (0.181,

3.153)

2.303)

0.333; 1.598 (0.619,

0.843; 1.102 (0.421,

4.125)

2.885)

0.664; 1.179 (0.561,

0.100; 1.000 (0.463,

2.480)

2.159)

0.112; 1.541 (0.906,

0.949; 1.020 (0.568,

2.623)

1.830)

0.676; 0.731 (0.169,

0.290; 0.332 (0.043,

3.172)

2.558)

0.369; 1.654 (0.552,

0.580; 1.380 (0.442,

4.959)

4.305)

0.123; 1.692 (0.868,

0.482; 1.307 (0.619,

3.301)

2.757)

0.041; 1.612 (1.021,

0.986; 1.004 (0.609,

2.545)

1.658)

0.450; 1.414 (0.575,

0.689; 0.816 (0.302,

3.475)

2.205)

0.532; 1.503 (0.419,

0.736; 1.264 (0.324,

5.392)

4.490)

4.36

8.72

13.08

Hormone therapy

Overall

Local

Regional

Distant

69

15

14

40

10.45

2.27

2.12

6.06

17

2

4

11

15.94

1.87

3.75

10.31

Radiation therapy

Overall

Local

Regional

79

22

10

12.62

3.52

1.6

23

6

3

19.34

5.04

2.52

87

Distant

47

7.51

15

0.065; 1.732 (0.967,

0.810; 1.083 (0.568,

3.100)

2.063)

0.013; 1.678 (1.115,

0.015; 1.699 (1.108,

2.524)

2.606)

0.279; 0.520 (0.159,

0.145; 0.405 (0.121,

1.698)

1.364)

0.104; 2.043 (0.863,

0.558; 1.310 (0.531,

4.837)

3.230)

0.003; 2.164 (1.290,

0.101; 1.607 (0.912,

3.629)

2.833)

12.61

Adjuvant radiation, hormone, and chemotherapy

Overall

Local

Regional

Distant

101

31

19

51

11.94

3.66

2.25

6.03

30

3

7

20

19.63

1.96

4.58

13.09

Abbreviations: AA, African-American; EA, European-American; HR, hazard rate; IR, incidence rate
(1000 person-years); CI, confidence interval.
Adjusted Cox hazard model variables: age at diagnosis, grade (1,2,3), and stage (I,II,III,IV).
*P values were calculated using the student t-test.

3.5.4 Recurrence rates among racially distinct breast cancer patients in different
stages
Overall incidence rates of recurrence were compared between AA and EA in both early (I–II) and
late stage (III-IV) breast cancer patients (Table 20). Our data revealed that AA displayed higher
recurrence rates than EA among stage I patients (p=0.001; HR: 2.165; CI: 1.348-3.476), even after
adjusting for age, grade, and stage (p=0.031; HR: 1.736; CI: 1.052-2.864). Among early stage (I-II)
patients, AA also exhibited higher recurrence rates than EA (p=0.002; HR: 1.793; CI: 1.252-2.567),
and trending higher in AA after controlling for age, grade, and stage (p=0.131; HR: 1.339; CI:
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0.917-1.956). Furthermore, AA displayed higher recurrence rates than EA among T1 classified
patients, irrespective of age, grade, and stage (p=0.003; HR: 2.009; CI: 1.263-3.197). Moreover,
unadjusted models reveal that AA displayed higher rates of recurrence than EA among N0
(p=0.005; HR: 1.777; CI: 1.186-2.661) and M0 (p=0.002; HR: 1.682; CI: 1.210-2.338) classified
patients. However, rates of recurrence were not significantly higher in AA as compared to EA
among late stage patients. Thus, these results suggest that AAs are at higher risk than EAs for
tumor recurrence among patients with non-invasive or minimally invasive breast cancer.

Table 20 Overall recurrence rates among racially distinct staged breast cancer patients

EA

p value; HR (95%

p value; HR (95%

CI)

CI)

Unadjusted Model

Adjusted Model

0.002; 1.793 (1.252,

0.131; 1.339 (0.917,

2.567)

1.956)

0.857; 0.934 (0.445,

0.637; 0.823 (0.366,

1.962)

1.850)

0.001; 2.165 (1.348,

0.031; 1.736 (1.052,

3.476)

2.864)

0.447; 1.239 (0.713,

0.823; 0.936 (0.523,

2.154)

1.674)

AA

n

IR

n

IR

130

11.14

39

19.08

Grouped stage

Early (I-II)

Late (III-IV)

31

55.17

9

50.65

Individual Stage

I

II

70

60

7.76

22.67

23

16

15.84

27.02

89

III

IV

25

6

48.01

145.8

7

2

0.902; 0.949 (0.410,

0.590; 0.774 (0.306,

2.195)

1.959)

0.822; 0.832 (0.167,

0.967; 0.964 (0.168,

4.152)

5.518)

N/A

N/A

<0.0001; 2.776

0.003; 2.009 (1.263,

(1.781, 4.326)

3.197)

0.504; 0.801 (0.419,

0.215; 0.647 (0.325,

1.534)

1.287)

0.215; 0.275 (0.035,

0.161; 0.228 (0.029,

2.115)

1.796)

0.680; 1.282 (0.394,

0.983; 1.015 (0.241,

4.173)

4.270)

0.005; 1.777 (1.186,

0.211; 1.319 (0.854,

2.661)

2.037)

0.201; 1.518 (0.801,

0.828; 1.079 (0.545,

2.877)

2.136)

0.744; 1.207 (0.391,

0.965; 0.970 (0.258,

3.719)

3.646)

45.01

90.29

TNM Staging
T
T0

2

130.83

0

N/A

T1

67

9.75

28

25.63

T2

T3

T4

54

12

9

28.48

49.67

106.73

11

1

4

22.3

13.31

121.36

N

N0

N1

N2

101

44

13

9.81

27.05

46.45

31

12

4

16.89

39.2

53.23

90

N3

5

55.06

1

0.742; 0.697 (0.081,

0.974; 0.962 (0.095,

5.970)

9.711)

0.002; 1.682 (1.210,

0.288; 1.210 (0.851,

2.338)

1.721)

0.822; 0.832 (0.167,

0.967; 0.964 (0.168,

4.152)

5.518)

43.27

M

M0

M1

157

6

12.82

145.8

46

2

20.8

90.29

Abbreviations: AA, African-American; EA, European-American; HR, hazard rate; IR, incidence
rate (1000 person-years); CI, confidence interval.
Adjusted Cox hazard model variables: age at diagnosis, grade (1,2,3), and stage (I,II,III,IV).
*P values were calculated using the student t-test.

3.5.5 Survival outcomes among racially distinct patients displaying recurrence
Survival duration after the initial recorded recurrence was compared between the racial groups
(Figure 28). AA exhibited only a very weak trend toward shorter survival time than EA after
experiencing their first episode of recurrence (p=0.231). The average time until death was
compared between EA and AA patients who experienced distant recurrences. Interestingly, AA
and EA patients exhibiting distant recurrence were comprised of similar percentages of alive
patients, however, AA (n=26) died considerably sooner than EA (n=80) (p=0.015). More precisely,
AA patients who experienced distant recurrences died approximately one year earlier than EA
distant recurrent patients. However patient numbers were too low to control for variables of age,
grade, and stage.
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Figure 28 AA exhibit lower survival duration than EA among recurrent breast cancer patients
Figure 28: (A) Survival time from first recurrence episode until death was compared between
AA and EA breast cancer patients. The log-rank analysis was conducted to determine statistical
differences between the racial groups. AA exhibited a weakly significant lower survival time
than EA (p=0.231). (B) The mean time (days) until death was compared between AA and EA
breast cancer patients displaying distant recurrence. AA died notably sooner than EA patients
(p=0.015). A t-test was performed to determine significant differences between the racial
groups.
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4
4.1

CONCLUSIONS

Conclusion part for neural growth model

Our analysis of the discrete probability distributions corresponding to stochastic neuronal growth
models indicates that the most important component of our model, namely the branching
probability p, has a clear impact on targeting performances. More precisely, the expected
success near the origin increases as a geometrical series with a factor of (1 + 𝑝). Furthermore,
the decrease in targeting performance at large distances approximately follows a geometrical
series with (1 + 3𝑝) and additional higher order corrections. In addition to computing the
values of the expected number of branches as a function of distance, we also determined an
expression for the corresponding variance values, as well as approximations for the optimal
targeting regions.
These probabilistic models are in excellent agreement with experimental data from the Firestein
laboratory and indicate that the parameters used in the theoretical model capture most of the
variability seen in the experimental data. One particularly interesting finding in this study is that
our model very accurately predicts dendrite growth for relatively young neurons in culture, at
days in vitro (DIV) 7 and 8. From our results, we can see that the estimate of growth rate varies
when we have different chemicals controlling the evolution process, for example, estimate of
branching probability of control is lower than that of Cypin. All the results from our model were
in the agreement with previous researches, which means our model can detect the change in the
regeneration process when the condition changes.
An interesting outcome of these results is to suggest that the logarithm of the number of active
branches might be a more appropriate way of constructing Sholl plots, as this transformation of
the expected values for the dendritic tree population is predicted to have a linear component
near the origin and approximate linear component at large distances. This is due to the fact that
logarithm transformation of geometric series results in linear sequences. The use of both of these
short and long-range components can provide a better statistical determination of branching
values, for example examining the data at those scales using linear regression models. If the
large-distance component is in disagreement with the predicted linear trend, this may indicate
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other effects, such as pruning at larger distances or parameter-dependent branching.
When neurons are injured in the brain or spinal cord, they may lose dendritic or axonal branches,
depending on the severity of the injury. Losing branching will disrupt the network and lead to a
loss of function. To this end, much work in regenerative neuroscience has focused on promoting
nerve growth after injury as a means of restoring function. Our goal with this computational
model is to better understand the rules that govern neuronal branching under control and injury
conditions and to confirm these findings with an in vitro system (cultured hippocampal neurons).
Future iterations of this model will allow us to determine whether promoting a particular type of
branching pattern – for example, that characteristic of treatment with BDNF – will allow a neuron
to best reach the target area after injury and become reintegrated with the network after injury.
Additionally, we were able to use these models to derive statistical tests for determining
differences between conditions, such as normal neurons versus neurons treated with growth
factors (e.g. BDNF; [60]) or neurons engineered to overexpress a particular protein (e.g. cypin;
[61, 62]). Such tests could replace the less informative methods currently used, including variance
analysis, which only provide information regarding statistical differences at specific distances as
opposed to analysis of the whole curve. In contrast, our analysis will produce a test of hypothesis
for relevant parameters, such as branching probability, in order to determine if different
experimental conditions produce changes in the fit values of these parameters that are
statistically significant. As an illustration, imagine comparing families of neurons with fewer
resources and a slower evolution speed to ones that have more resources but a higher growth
speed; while the branching rates are similar, the dendritic trees become scaled up or scaled down
versions of each other. The resulting Sholl curves would have the same overall shape but are
“stretched out” or “compressed” when compared to each other. In this imagined scenario, the
ANOVA analysis would indicate statistical differences between these two types of Sholl curves at
many locations without providing any intuition about their similarities.
In the future, we will continue to apply our model on different neuron growth process controlled
by the same chemical, but with different concentration. By doing this, we will be able to
quantitatively connect the change in branching probability with the change in the concentration.
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This will definitely be useful in the future in the clinical practice, in order to help to control the
development of neuron cells.

4.2

Conclusion part for tumor growth model

The relation between tumor size and biological parameters has been well documented and
widely used in prognostication. However, less attention was paid on the effect of
clinicopathological factors, such as grade, stage, ki_67 score, on the in vivo breast cancer growth
rate [63-67].
This study was aimed not only to reaffirm our current knowledge but also to explore the impact
of more novel histological biomarkers on tumor growth rate. Of particular interest was the
balance between pro-apoptotic and anti-apoptotic signaling proteins. Those investigated were
the proliferative marker Ki67 and the apoptotic marker cleaved Caspase-3, an activated protease
enzyme acting in the late stages of the apoptotic pathway. [68] Additionally, the correlation
between growth rates – calculated as the change in volume over time across sequential
mammograms - and ER, PR, and HER-2 status were investigated, as well as that of the basal
marker CK 5/6. However, one problem with studies looking at early screen-detected tumors is
that, by their very nature, most tumors being investigated will be small slower-growing Luminal
tumors, expressing mostly ER and PR (75% of cases). This made the study somewhat biased, as
very few tumors of the HER-2 or basal (CK 5/6 expressing) or TNBC subtypes were studied (8.7%,
4% and 12% of cases respectively). These tumor subtypes are typically more aggressive and much
faster growing, making them far less likely to be screening detected [69,70]. It was, therefore,
difficult to establish significant correlations between these markers/subtypes and other
parameters.
Interestingly, different studies looking at patient outcome have used a wide range of different
positive/negative cut-off points for both Ki67 and apoptotic marker staining. This has led to
debate as to the most appropriate cut- off point. Some studies have proposed that the cut-off
should vary depending on the clinical objective of the study.[71-73]
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Few studies have looked at the growth rate in terms of the balance between pro-and antiapoptotic signaling proteins, and so no consensus on cut-off has been agreed in this context. In
this study, in order to keep the data as unbiased as possible, Ki67 and cleaved Caspase-3 were
analyzed as continuous variables. It was shown that increasing Ki67 expression correlated
significantly with increased tumor growth rate. This was to be expected, with Ki67 being a
proliferative marker expressed during all active phases of the cell cycle, peaking during the
mitotic phase. [71-74] A significant association was also seen between cleaved Caspase-3 and
growth rate. Moreover, Cleaved Caspase-3 was found to positively correlate with Ki67 expression,
suggesting that an increase in proliferative markers in breast tumor cells is usually accompanied
by an increase in apoptotic proteins as a counter-balancing measure. A previous larger breast
cancer study showed similar observations. [75]
Correlations were observed between growth rate and tumor grade and mitotic index. The
relationship with grade has previously been observed in many studies and reflects the fact that
mitotic index is the most powerful component of tumor grade. [74, 76] In fact, some studies have
shown tumor size to be positively correlated with Ki67 expression, whilst have others found no
significant relationship. [74] Degree of vascular invasion also significantly correlated with growth
rate. This is accounted for by the increased provision of nutrients to the tumor cells from the
newly invaded blood vessels, allowing a greater degree of cell proliferation. Other studies have
made similar findings, and it has been shown that extensive vascular invasion is also closely
related to poorer prognosis, and pronounced Ki67 expression. [76]
A previous study adopted an approach to measure tumor growth rate as the change in tumor
size over time in only one dimension – the largest tumor dimension. [77] However this method
introduced considerable inaccuracy into the growth rate calculations and was based on the
assumption that the proportional increase in tumor size was the same in all three dimensions. In
fact, it has been shown that growth rate is influenced heavily by stromal-tumor interactions and
the presence of limiting anatomical barriers. [78, 79] A tumor thus is unlikely to grow uniformly
in all directions, and will most probably favor the direction of least resistance. A more accurate
approach would have been to measure the change in tumor size in two or even three dimensions
(tumor volume) if possible. Here we calculate tumor volume from mammogram readings. We
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assumed the breast cancer tumor to be ellipsoidal and the highest mammogram reading was
assumed as height and the other as diameter. The tumor volumes were between 9 to 37819mm3
with a mean of 4591.74mm3. Thus the tumor volume calculated could serve as a factor for
demonstrating the tumor expansion rate rather than tumor size alone, which is a biased
parameter. [80]
Interestingly, a previous study has suggested that tumor growth rate, independent of stromal
interactions, is non-linear, and grows in a so-called “stepwise” manner, undergoing phases of
relative stability intermittently interrupted by sudden surges in growth. It is proposed that these
periods of inactivity may be due to: (a) periods of balanced proliferation and apoptosis, or (b)
periods when the growth fraction is zero. The latter would presumably be accompanied by a
massively decreased expression of proliferative signaling proteins such as Ki67. [81] In this study,
the mean time between screening and diagnosis was just 18 months. In future studies growth
rate could be calculated over a longer time period, offering a more accurate long-term picture of
changes in tumor volume.
In our study, we observed a significant correlation between breast cancer subtypes and tumor
growth rate. Tumor growth rate varied significantly between the subtypes with higher growth
rate among TNBC patients. Thus, the growth rate may be a significant consideration when we try
to separate the breast cancer into different subtypes.
Furthermore, we investigated the relationship between growth rate and patient outcome. Our
analysis revealed that increase in growth rate increases the risk to death. However, the tumor
growth rate has not been implicated as a prognostic variable in clinical practice because of its
difficulty in evaluating it in the short interval of diagnosis and treatment. Many studies have
addressed that faster growing tumors have a worse survival. [24, 82-84] However, some studies
demonstrated that there is no any association of tumor growth rate with patient’s survival. [25]
Also, in the other study carried out by Tubiana et.al, there was no any survival difference between
the subgroups of patients with rapid or intermediate growth rate after the follow-up exceeding
8 years [26].
One final avenue that could be explored more is the possible correlations between growth rate
97

and other aspects of mammographic appearance, and also between biomarker expression and
mammographic appearance. Some work has already been done in this area, which shows that
luminal tumors showed more speculate lesions on mammographic shadow, whilst HER-2 positive
and basal tumors were characterized by more ill-defined masses on mammography. [57, 66]
However there is certainly scope for further investigation in this area, looking at density,
calcifications, and other features.
In conclusion, the study has demonstrated the relationship between breast cancer growth rate
and the expression of the proliferative marker Ki67. Well-documented relationships between
various biomarkers and clinicopathological parameters classically used in breast cancer
prognostication have also been reaffirmed. The activity of the pro-apoptotic protein cleaved
Caspase-3 in counterbalancing proliferative activity – controlled by Ki67 – was clearly observed.
Overall the study proposes that growth rate is a significant consideration when separating the
type of breast carcinomas, provide the basis for further refinement of the current classification
system, as well as the discovery of new molecular subtypes and consequently, it is important in
determining patient outcome. This study has revealed prognostic information and evidencebased data that can be used in the medicolegal practice.

4.3

Conclusion from extending survival analysis on breast cancer recurrence

Our analysis revealed higher incidence rates of recurrence in AA compared to EA among patients
that received any combination of adjuvant therapy. Moreover, our data demonstrates an
increased risk of tumor recurrence in AA than EA among patients diagnosed with minimally
invasive disease. Additionally, this is the first clinical study to suggest that neoadjuvant
chemotherapy improves breast cancer recurrence rates and patterns in AA.
This clinical study is the first extensive investigation into the rates and patterns of tumor
recurrence in breast cancer patients following conventional treatments among racially distinct
populations. Our study has revealed notable distinctions in recurrence patterns among EA and
AA patients. First, AA displayed considerably higher rates of recurrence than EA. Second,
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intriguingly, we observed higher severity in recurrence patterns displayed by AA for whom we
discerned stronger trends in AA of tumor recurrence to regional and distant sites. This trend was
evident after patients received radiation, hormone, and any combination of adjuvant therapies.
Overall, these observed trends were quite significant since local recurrence tends to elicit a more
favorable clinical prognosis compared to distant recurrence, while the latter trends type precedes
a poorer clinical prognosis. Triple-negative breast cancer (TNBC) patients have been shown to
display an increased risk for recurrence and particularly for recurrence to distant sites, while nonTNBC patients exhibit higher trends of recurrence to local sites [58]. These findings parallel our
observations of an increased risk of overall and especially distant recurrence in AA, as well as an
increased risk of local recurrences in EA. This tendency reflects the well-reported higher
incidence of TNBC phenotypes in AA patients and a higher prevalence of non-TNBC subtypes in
EA patients. Furthermore, we observed a trend of a higher number of recurrence episodes in AA
compared to EA. The more recurrence episodes of the patient experiences, the more fatal the
outcome is likely to be, and the more the patient’s quality of life is potentially compromised.
Additionally, we discerned stronger inclinations of distant recurrence to multiple organs in AA
compared to EA. These observed aggressive recurrence patterns reveal that AA patients exhibit
an increased prospect of a poor clinical prognosis, theoretically contributing to their higher
mortality rates than EA patients. Recurrence rates were also found to be higher in AA than EA
among early stage, minimally invasive breast cancer patients, irrespective of age, grade, or stage.
This data presents an intriguing paradox as the advanced stage upon diagnosis is typically
associated with increased risk for recurrence. Thus, these findings suggest that AA patients of all
clinical stages should be closely evaluated for the prospect of tumor recurrence. Neoadjuvant
chemotherapy seemed to reverse these observed recurrence trends. Among patients who
received neoadjuvant chemotherapy, AA displayed a lower rate of recurrence than EA; however
due to a low number of recorded patients that received neoadjuvant chemotherapy, statistical
significance was diminished. In addition, higher incidences of aggressive recurrence patterns in
AA were notably attenuated after these patients underwent neoadjuvant chemotherapy. This
data suggest preoperative chemotherapy may reduce the severity of recurrence rates and
patterns in AA patients. This study suggests that neoadjuvant chemotherapy should be
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recommended for AA patients who are at higher risk for developing tumor recurrence. A recent
clinical study reported that in fact, neoadjuvant chemotherapy is administered more frequently
to AA than EA patients likely as a result of their higher prevalence of advanced stage, grade, and
triple negative receptor status [59]. Biological research is needed to be conducted to understand
the molecular basis underlying inequalities in recurrence patterns among EA and AA patients for
potential therapeutic targets. Augmented prognosticative clinical measures need to be exploited
in order to foretell the likelihood of disease recurrence. Hence, rigorous and intensive supervision
of the prospect of recurrence is conceivably compulsory to palliate the elevated risk of recurrent
breast cancer demonstrated by AA patients.
Although prior clinical studies have exposed disparities in recurrence risk among EA and AA, this
study is one of the first to uncover distinctions in rates and patterns of tumor recurrences
following conventional forms of breast cancer treatments among the racial groups and thus
highlights the need for further investigation and surveillance. Our comprehensive analysis has
also illuminated previously unrecognized differences in the rates and patterns of recurrence postchemotherapy among racially distinct populations by suggesting that AAs respond better to
neoadjuvant chemotherapy. Additionally, no study has yet elucidated the significantly higher risk
for recurrence among early stage AA patients. Overall, this study further advocates that race
should be considered among the potential decisive risk factors in the clinic for recurrence.
Awareness of the higher rate of recurrence in AA may compel clinicians to consider race as a
critical factor in evaluating the prospect of cancer returning after patients enter remission, and
allow this factor to play a major role in treatment decisions. Hereinafter, enriched comprehensive
screening programs and tailored treatment plans may be imperative to impede augmented the
risk of tumor recurrence and aggressive recurrence patterns in AA patients that may be
reinforcing their poor clinical outcomes.

100

REFERENCES
[1] Philip J. Horner & Fred H. Gage (2000) Regenerating the damaged central nervous system.
Nature 407, 963-970 (26 October 2000) | doi:10.1038/35039559.
[2] Maskery S, Buettner HM, Shinbrot T (2004) Growth cone pathfinding: a competition
between deterministic and stochastic events. BMC Neurosci 5:22:31.
[3] Borisyuk R, Cooke T, Roberts A (2008) Stochasticity and functionality of neural systems:
mathematical modelling of axon growth in the spinal cord of tadpole. Biosystems 93: 101–114.
[4] Uylings HBM, and Van Pelt J (2002). Measures for quantifying dendritic arborizations.
Network: Comput. Neural Syst. 13: 397-414.
[5] Krottje JK, van Ooyen A (2007) A mathematical framework for modeling axon guidance.
Bulletin of Mathematical Biology 69: 3–31.
[6] O'Neill KM, Akum BF, Dhawan ST, Kwon M, Langhammer CG, and Firestein BL (2015) Assessing
effects on dendritic arborization using novel Sholl analyses. Frontiers in Cellular Neuroscience,
9:285.
[7] Hentschel HGE, van Ooyen A (1999) Models of axon guidance and bundling during
development. Proceedings of the Royal Society B-Biological Sciences 266: 2231–2238.
[8] Borisyuk R, Cooke T, Roberts A (2008) Stochasticity and functionality of neural systems:
Mathematical modelling of axon growth in the spinal cord of tadpole. Biosystems 93: 101–114.
[9] van Ooyen A (2011) Using theoretical models to analyse neural development (vol 12, pg 311,
2011). Nature Reviews Neuroscience 12.
[10] Zubler F, Douglas R (2009) A framework for modeling the growth and development of
neurons and networks. Frontiers in Computational Neurosci- ence 3.

101

[11] Langhammer CG, Previtera ML, Sweet ES, Sran SS, Chen M, and Firestein BL (2010)
Automated Sholl analysis of digitized neuronal morphology at multiple scales: whole cell Sholl
analysis versus Sholl analysis of arbor subregions. CytometryPartA 77A: 1160–1168.
[12] Oşan R, Su E, Shinbrot T. (2011) The interplay between branching and pruning on neuronal
target search during developmental growth: functional role and implications. PLoS One.
6(10):e25135.
[13] Lecture Notes for Introductory Probability Janko Gravner
[14] Carey, L.A., et al., Race, breast cancer subtypes, and survival in the Carolina Breast Cancer
Study. Jama, 2006. 295(21): p. 2492-502.
[15] de Ronde, J.J., et al., Concordance of clinical and molecular breast cancer subtyping in the
context of preoperative chemotherapy response. Breast Cancer Res Treat, 2010. 119(1): p. 11926.
[16] Beral, V., et al., Hormone replacement therapy and high incidence of breast cancer between
mammographic screens. Lancet, 1997. 349(9058): p. 1103-4.
[17] Hin-Peng, L., Diet and breast cancer: an epidemiologist's perspective. Crit Rev Oncol Hematol,
1998. 28(2): p. 115-9.
[18] Pharoah, P.D., et al., Family history and the risk of breast cancer: a systematic review and
meta-analysis. Int J Cancer, 1997. 71(5): p. 800-9.
[19] Spratt, J.S., J.S. Meyer, and J.A. Spratt, Rates of growth of human solid neoplasms: Part I. J
Surg Oncol, 1995. 60(2): p. 137-46.
[20] Berry, D.A., et al., Effect of screening and adjuvant therapy on mortality from breast cancer.
N Engl J Med, 2005. 353(17): p. 1784-92.
[21] Baker, L.H., Breast Cancer Detection Demonstration Project: five-year summary report. CA
Cancer J Clin, 1982. 32(4): p. 194-225.

102

[22] Holland, R., et al., So-called interval cancers of the breast. Pathologic and radiologic analysis
of sixty-four cases. Cancer, 1982. 49(12): p. 2527-33.
[23] Freimanis, R.I. and M. Yacobozzi, Breast cancer screening. N C Med J, 2014. 75(2): p. 117-20.
[24] Bailar, J.C., 3rd and E.M. Smith, Progress against cancer? N Engl J Med, 1986. 314(19): p.
1226-32.
[25] Yoo, T.K., et al., In Vivo Tumor Growth Rate Measured by US in Preoperative Period and Long
Term Disease Outcome in Breast Cancer Patients. PLoS One, 2015. 10(12): p. e0144144.
[26] Tubiana, M., et al., Growth rate, kinetics of tumor cell proliferation and long-term outcome
in human breast cancer. Int J Cancer, 1989. 44(1): p. 17-22.
[27] Arnerlov, C., et al., Breast carcinoma growth rate described by mammographic doubling time
and S-phase fraction. Correlations to clinical and histopathologic factors in a screened population.
Cancer, 1992. 70(7): p. 1928-34.
[28] Boyd, N.F., et al., Clinical estimation of the growth rate of breast cancer. Cancer, 1981. 48(4):
p. 1037-42.
[29] Locopo, N., M. Fanelli, and G. Gasparini, Clinical significance of angiogenic factors in breast
cancer. Breast Cancer Res Treat, 1998. 52(1-3): p. 159-73.
[30] Casey, T., et al., Molecular signatures suggest a major role for stromal cells in development
of invasive breast cancer. Breast Cancer Res Treat, 2009. 114(1): p. 47-62.
[31] Galante, E., et al., Growth rate of primary breast cancer and prognosis: observations on a 3to 7-year follow-up in 180 breast cancers. Br J Cancer, 1986. 54(5): p. 833-6.
[32] Kristek, J., et al., Tumor growth fraction, expression of estrogen and progesterone receptors,
p53, bcl-2 and cathepsin D activity in primary ductal invasive breast carcinoma and their axillary
lymph node metastases. Coll Antropol, 2007. 31(4): p. 1043-7.
[33] Marušić M, Vuk-Pavlović S (1993) Prediction power of mathematical models for tumor
growth. J Biol Syst 1: 69–78
103

[34] Olea N, Villalobos M, Nuñez MI, Elvira J, Ruiz de Almodóvar JM, et al. (1994) Evaluation of
the growth rate of MCF-7 breast cancer multicellular spheroids using three mathematical models.
Cell Prolif 27: 213–223
[35] Wallace DI, Guo X (2013) Properties of tumor spheroid growth exhibited by simple
mathematical models. Front Oncol 3: 51
[36] Vaidya VG, Alexandro FJ (1982) Evaluation of some mathematical models for tumor growth.
Int J Biomed Comput 13: 19–36
[37]Laird AK (1965) Dynamics of tumour growth: comparison of growth rates and extrapolation
of growth curve to one cell. Br J Cancer 19: 278–291
[38]

Keshgegian, A.A. and A. Cnaan, Proliferation markers in breast carcinoma. Mitotic figure

count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol, 1995.
104(1): p. 42-9.
[39] Brent A. Williams, MS, Jayawant N. Mandrekar, PhD, Sumithra J. Mandrekar, PhD, Stephen
S. Cha, MS, Alfred F. Furth, MS , (June 2006) Finding Optimal Cutpoints for Continuous Covariates
with Binary and Time-to-Event Outcomes
[40] Manish Kumar Goel, Pardeep Khanna, and Jugal Kishore. Understanding survival analysis:
Kaplan-Meier estimate. Int J Ayurveda Res. 2010 Oct-Dec; 1(4): 274–278.
[41] Ahmad A. Pathways to breast cancer recurrence. ISRN Oncol. 2013;2013:290568.
[42] Gerber B, Freund M, Reimer T. Recurrent breast cancer: treatment strategies for maintaining
and prolonging good quality of life. Dtsch Arztebl Int . 2010;107(6):85-91.
[43] Keenan T, Moy B, Mroz EA, et al. Comparison of the Genomic Landscape Between Primary
Breast Cancer in African American Versus White Women and the Association of Racial Differences
With Tumor Recurrence. J Clin Oncol, 2015;33(31):3621-7.
[44] Breslow, NE. Analysis of Survival Data under the Proportional Hazards Model. Int Stat Rev.
1975; 43(1): 45–57.

104

[45] Cox, DR. Regression Models and Life-Tables. J R Stat Soc Series B Stat Methodol. 1972;
34(2):187–220.
[46] Carrel et al. (2009). NOS1AP Regulates Dendrite Patterning of Hippocampal Neurons through
a Carboxypeptidase E-Mediated Pathway. J Neurosci. 2009 Jun 24; 29(25): 8248.
[47] Kutzing et al., 2010. Automated Sholl analysis of digitized neuronal morphology at multiple
scales. J Vis Exp. 2010 Nov 14;(45). pii: 2354. doi: 10.3791/2354.
[48] Langhammer et al., 2010, Automated Sholl analysis of digitized neuronal morphology at
multiple scales: Whole cell Sholl analysis versus Sholl analysis of arbor subregions. Cytometry A.
2010 Dec;77(12):1160-8. doi: 10.1002/cyto.a.20954.
[49] Firestein et al., 1999. Cypin: a cytosolic regulator of PSD-95 postsynaptic targeting. Neuron.
1999 Nov;24(3):659-72.
[50]

Rakha, E.A., et al., Triple-negative breast cancer: distinguishing between basal and

nonbasal subtypes. Clin Cancer Res, 2009. 15(7): p. 2302-10.
[51] Douglas G Altman , The logrank test J Martin Bland, BMJ, 2004 May 1;328(7447): 1073
[52] RhoA Regulates Dendrite Branching in Hippocampal Neurons by Decreasing Cypin Protein
Levels Hongxin Chen and Bonnie L. Firestein
[53] Landgraf M and Evers JF (2005) Control of dendritic diversity. Current Opinion in Cell Biology
17: 690–696.
[54] Kutzing MK, Langhammer CG, Luo V, Lakdawala H, and Firestein BL (2010) Automated Sholl
analysis of digitized neuronal morphology at multiple scales. J Visual Exp 45: 2354.
[55] Maxine Chen, Kenyatta G. Lucas, Barbara F. Akum, Gaithri Balasingam, Tamara M. Stawicki,
Janine M. Provost, Gary M. Riefler, Rebecka J. Jörnsten, and Bonnie L. Firestein. A Novel Role for
Snapin in Dendrite Patterning: Interaction with Cypin. Mol Biol Cell. 2005 Nov; 16(11): 5103–5114.
[56] Roberto Malinow, Yasunori Hayashi, Mirjana Maletic-Savatic, Shahid H. Zaman, JeanChristophe Poncer, Song-Hai Shi, José A. Esteban, Pavel Osten, and Ken Seidenman, Introduction
105

of Green Fluorescent Protein (GFP) into Hippocampal Neurons through Viral Infection, Cold
Spring Harb Protoc. 2010 Apr;2010(4):pdb.prot5406. doi: 10.1101/pdb.prot5406.
[57] Neuronal nitric oxide synthase: Structure, subcellular localization, regulation, and clinical
implications Li Zhou, Dong-Ya Zhu
[58] Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and
patterns of recurrence. Clin Cancer Res. 2007;13(15, pt 1):4429-34.
[59] Killelea BK, Yang VQ, Wang SY, et al. Racial Differences in the Use and Outcome of
Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. J
Clin Oncol. 2015;33(36):4267-76.
[60] Kwon, M., et al., BDNF-promoted increases in proximal dendrites occur via CREB-dependent
transcriptional regulation of cypin. Journal of Neuroscience, 2011.31(26): p 9735-9745
[61] Akum, B.F., et al., Cypin regulates dendrite patterning in hippocampal neurons by promoting
microtubule assembly. Nature Neuroscience, 2004. 7(2): p. 145-152.
[62] O’Neill, K.M., et al., Assessing effects on dendritic arborization using novel Sholl analyses.
Frontiers in Cellular Neuroscience, 2015. 9:p.285
[63] Blamey, R.W., et al., Survival of invasive breast cancer according to the Nottingham
Prognostic Index in cases diagnosed in 1990-1999. Eur J Cancer, 2007. 43(10): p. 1548-55.
[64] Elston, C.W., I.O. Ellis, and S.E. Pinder, Pathological prognostic factors in breast cancer. Crit
Rev Oncol Hematol, 1999. 31(3): p. 209-23.
[65] Fitzgibbons, P.L., et al., Prognostic factors in breast cancer. College of American Pathologists
Consensus Statement 1999. Arch Pathol Lab Med, 2000. 124(7): p. 966-78.
[66] Perou, C.M., et al., Molecular portraits of human breast tumours. Nature, 2000. 406(6797):
p. 747-52.
[67] Taneja, S., et al., The mammographic correlations of a new immunohistochemical
classification of invasive breast cancer. Clin Radiol, 2008. 63(11): p. 1228-35.
106

[68] Kobayashi, T., et al., Prognostic significance of the immunohistochemical staining of cleaved
caspase-3, an activated form of caspase-3, in gliomas. Clin Cancer Res, 2007. 13(13): p. 3868-74.
[69] Hu, Z., et al., The molecular portraits of breast tumors are conserved across microarray
platforms. BMC Genomics, 2006. 7: p. 96.
[70] Sorlie, T., Molecular portraits of breast cancer: tumour subtypes as distinct disease entities.
Eur J Cancer, 2004. 40(18): p. 2667-75.
[71] de Azambuja, E., et al., Ki-67 as prognostic marker in early breast cancer: a meta-analysis of
published studies involving 12,155 patients. Br J Cancer, 2007. 96(10): p. 1504-13.
[72] MacGrogan, G., et al., Comparison of quantitative and semiquantitative methods of
assessing MIB-1 with the S-phase fraction in breast carcinoma. Mod Pathol, 1997. 10(8): p. 76976.
[73] Spyratos, F., et al., Correlation between MIB-1 and other proliferation markers: clinical
implications of the MIB-1 cutoff value. Cancer, 2002. 94(8): p. 2151-9.
[74] Urruticoechea, A., I.E. Smith, and M. Dowsett, Proliferation marker Ki-67 in early breast
cancer. J Clin Oncol, 2005. 23(28): p. 7212-20.
[75] Lipponen, P., et al., Apoptosis in breast cancer as related to histopathological characteristics
and prognosis. Eur J Cancer, 1994. 30a(14): p. 2068-73.
[76] Pinder, S.E., et al., Assessment of the new proliferation marker MIB1 in breast carcinoma
using image analysis: associations with other prognostic factors and survival. Br J Cancer, 1995.
71(1): p. 146-9.
[77] Brekelmans, C.T., et al., Histopathology and growth rate of interval breast carcinoma.
Characterization of different subgroups. Cancer, 1996. 78(6): p. 1220-8.
[78] Kim, J.B., R. Stein, and M.J. O'Hare, Tumour-stromal interactions in breast cancer: the role
of stroma in tumourigenesis. Tumour Biol, 2005. 26(4): p. 173-85.

107

[79] Silberstein, G.B., Tumour-stromal interactions. Role of the stroma in mammary development.
Breast Cancer Res, 2001. 3(4): p. 218-23.
[80] Richtig, E., et al., Calculated tumour volume as a prognostic parameter for survival in
choroidal melanomas. Eye (Lond), 2004. 18(6): p. 619-23.
[81] Speer, J.F., et al., A stochastic numerical model of breast cancer growth that simulates clinical
data. Cancer Res, 1984. 44(9): p. 4124-30.
[82] Heuser, L.S., et al., The association of pathologic and mammographic characteristics of
primary human breast cancers with "slow" and "fast" growth rates and with axillary lymph node
metastases. Cancer, 1984. 53(1): p. 96-8.
[83] Olsson, A., et al., Tumour-related factors and prognosis in breast cancer detected by
screening. Br J Surg, 2012. 99(1): p. 78-87.
[84] Spratt, J.S. and S.W. Spratt, Medical and legal implications of screening and follow-up
procedures for breast cancer. Cancer, 1990. 66(6 Suppl): p. 1351-62.

108

